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Summary 
A novel series of 2’,4’,6’-trimethoxychalcone derivatives were prepared using one-
step Claisen-Schmidt condensations of aldehydes with methyl ketones. The 
compounds were evaluated for effects against malaria, 15-lipoxygenase and radical 
scavenging activity. Of the twenty-five chalcone derivatives, only one exhibited 
significant scavenging of DPPH radical: E-1-(2,4,6-trimethoxyphenyl)-3-(3,4-
dihydroxyphenyl)-2-propen-1-one (44). Almost all chalcone compounds showed 
potent inhibition of 15-lipoxygenase.  
Two 2’,4’-dimethoxy-6’-hydroxychalcone derivatives were synthesized by the same 
method. In most cases, chalcones containing a 6’-hydroxyl group cyclized 
spontaneously to chromanone. This provided four chroman-4-one derivatives, which 
were alkylated to yield chromanol derivatives. Hydrogenation of the chromanols 
afforded the corresponding chromans.  
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Abbrevations 
b   broad 
calc.   calculated 
conc.   concentrated 
COSY  correlated spectroscopy  
δ   chemical shift (in ppm) 
d   doublet 
∆   heat 
DCM   dichloromethane 
DEPT   distortionless enhancement by polarization transfer 
DHP   3,4-dihydro-2H-pyran 
DMP   Dess Martin periodinane 
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DPPH•  diphenylpicrylhydrazyl radical 
EI   electron bombardment ionisation 
EtOAc  ethyl acetate 
h/hrs   hour/hours 
HRMS  high resolution mass spectroscopy 
IR   infrared spectroscopy 
J   coupling constant (in Hz) 
LDL   low density lipoprotein 
lit.   literature 
LO   lipoxygenase 
m   multiplet 
m/z   mass/charge 
min   minutes 
mp   melting point 
MS   mass spectroscopy 
n.d.   not determined 
NMR   nuclear magnetic resonance 
ppm   parts per million 
ROS   reactive oxygen species 
s   singlet 
t   triplet 
p-TsOH  para-toluenesulphonic acid 
THF   tetrahydrofuran 
THP   tetrahydropyran 
TLC   thin layer chromatography 
TMS   trimethylsilyl 
νmax   infrared absorption frequency (in wavenumbers: cm-1) 
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1. Introduction 
1.1 Flavonoids 
Flavonoids have been known for more than a hundred years, and constitute one of the 
largest and most diverse groups of natural phenols. The flavonoids are usually 
yellow-coloured compounds, and contribute to the colours of flowers and fruits. 
Their biological activity was discovered around 1940 and they were for a short while 
designated “P vitamins” because of their ability to heal capillary fragility, a property 
similar to that of vitamin C. This effect was never entirely proven, but since then their 
biological role has been studied extensively, and thousands of articles and several 
books have been published on the theme.1  
Flavonoids occupy a variety of structural forms, which have the flavan skeleton 
structurally in common, see Figure 1.  
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Figure 1. The structure and numbering pattern of flavan 
Flavonoids show a wide variety of biological activities. In addition to their 
antioxidant effects,2 they have been reported to among other things modulate enzyme 
activity,3 have immunomodulating and anti-inflammatory activities,4 antibiotic 
effects,5 oestrogenic activity,6 anticarcenogenic activity,7 antithrombotic effects8 and 
counteract vascular permeability.9 Silybin (1), a flavonoid from the milk thistle 
Silybum marianum, has hepatoprotective effect and is used in combination with 
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penicillin in the treatment of mushroom poisoning. Drugs containing milk thistle 
extract are used to treat various types of liver disease.10 
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Figure 2. Silybin (1) - a flavonoid in therapeutic use 
Chalcones, often entitled ‘open chain flavonoids’, possess a 1,3-diphenyl-2-propen-1-
one skeleton. With regard to substituents the carbon atoms of the benzene rings are 
numbered as shown in Figure 3, which is the pattern adopted by Chemical Abstracts. 
It should be noted that the numbering in the chalcone framework is reversed from 
that of the other flavonoids. The bridge carbons are marked relative to the carbonyl 
function as C-α and C-β.  
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Figure 3. The basic skeleton and numbering pattern of chalcones I and chromans II 
In plants, chalcones are important intermediates in the biosynthesis of flavonoids. 
Chalcones have shown a wide range of biological activities depending on the 
substitution pattern on the two aromatic rings. These include antibiotic,11 modulation 
of enzyme activity,12 modulation of P-glycoprotein mediated multidrug resistance,13 
tuberculostatic,14 antileishmanial,15 oestrogenic,16 anticarcinogenic,17 anti-
inflammatory18 and antimalarial activity.19  
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Derivatives of flavan, in which the B ring has been replaced by other ring structures 
or aliphatic chains are designated chromans. Chromans having a carbonyl group at C-
4 are named chromanones. 
1.2 Robustadial 
The structural elucidation of the naturally occurring chroman derivatives robustadials 
A and B20 combined with a general interest in oxygen heterocycles, triggered 
Skattebøl and Aukrust to attempt their synthesis. While the robustadials A and B 
were first isolated in 1984, their structures were not correctly established until 1988.21 
Robustadial A and B (2) are diastereomeric chroman derivatives from the leaves of 
Eucalyptus robusta, and they have been reported to exhibit antimalarial properties. 
O
OH
HO
O
O
2  
Figure 4. The structure of robustadials A and B 
Aukrust and Skattebøl described a synthesis of robustadial A in 1996.22 According to 
the depicted retrosynthetic route (Figure 5), a chromanone bearing the general 
structure 3 would serve as an intermediate.  
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Figure 5. Retrosynthesis of robustadials 
The synthetic scheme involved four steps starting from phloroglucinol and an α,β-
unsaturated acid derivative via the corresponding chromanone 3. The isobutyl group 
was attached with methallylzinc bromide, followed by hydrogenation, yielding the 
desired chroman 4. The formylation step produced the target molecule 2.  
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Figure 6. Alternative retrosynthesis of chromanone intermediates 
Retrosynthetic studies revealed that chalcones with the general structure 5 served as 
valuable intermediates towards analogues of robustadial A and B. The starting 
material would then consist of substituted acetophenone and an aromatic aldehyde. 
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Thus, there are several ways towards the synthesis of robustadial intermediates 
bearing chalcone or chroman skeletons. 
1.3 Searching for new therapies 
There is urgent demand for novel and improved therapeutical compounds in many 
medicinal fields. The search for new drugs can be started in a rational way by 
identifying a biological target, i.e. an enzyme, which is essential for the pathological 
process. Modulators of enzyme activity can be designed based on the structural 
knowledge about the target enzyme. By identifying the structural requirements that 
might be necessary for the molecule to exert an effect on the target, one can construct 
a molecule containing these structural features. This lead compound then serves as a 
template for other potentially bioactive compounds. By testing derivatives in which 
the chemical structure of the lead has been modified, the optimal structural 
requirements for pharmacological activity might be identified and a potential drug 
agent unveiled. This was the case for the recent unearthing of the malaria protease 
inhibitory activity of certain chalcones.23 Using a model structure of a parasitic 
protease, chalcones and their derivatives were identified as potential antimalarials. In 
vitro testing demonstrated antimalarial activity for several of the compounds, 
supporting the predicted structure-activity relationship. 
Very few drugs have been developed on a rational basis despite more detailed 
knowledge of potential targets, such as three-dimensional structures of enzymes, 
metabolic pathways, and genome sequences. To date, most pharmaceuticals have 
been developed in an empirical way and their targets identified afterwards. This 
pathway involves screening of large libraries of chemicals and examination of plant 
extracts. Often, one identifies the constituents of herbal remedies used in traditional 
medicine and validates their biological activity against the maladies that the plants are 
used to treat. Pharmacologically active, natural substances often serve as models for 
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the synthesis of compounds that retain or improve the pharmacological properties. 
The development of the anti-inflammatory drug sodium cromoglycate (6) is an 
excellent example of this. It was derived from the structure of a naturally occurring 2-
chromen-4-on, khellin, formerly used to treat stomach complaints and asthma. 
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Figure 7. Sodium cromoglycate (6) - an anti-inflammatory drug derived from a naturally 
occurring flavonoid. 
Simple analogues of robustadial have shown antimalarial effects, albeit weak,24 and 
recent reports give evidence of the antimalarial effects of some chalcone derivatives. 
Flavonoids have shown antioxidative and enzyme-inhibitory properties which may be 
beneficial in the prevention of coronary heart disease, inflammatory conditions, and 
cancer. With this in mind, we set about to synthesize chalcone and chroman 
derivatives that were subjected to biological testing. In this study, focus has been on 
the antimalarial activities of the synthesized compounds, their radical scavenging 
properties and their inhibition of the enzyme 15-lipoxygenase (15-LO). 
The next sections contain brief reviews of the pathology of malaria and conditions 
that are associated with radical-mediated and oxidative processes: inflammation and 
atherosclerosis.  
1.4 Malaria 
The World Health Organization (WHO) estimates that globally about 500 million 
individuals suffer from acute cases of malaria and, at a minimum, 1 million – more 
probably 2 million - people die from malaria every year. The majority of deaths, at 
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least 70 %, are among children under the age of five living in sub-Saharan Africa. 
Today, 90 % of all fatalities due to malaria are found in this region.25 In addition, 
Africa includes the majority of the world’s poorest countries. Malaria is a curable 
disease if the illness is diagnosed and treated at an early stage, but in countries 
lacking a sustainable infrastructure, medical expertise, and basic services, very few 
have access to effective and affordable therapy.    
The rapid increase in resistance to commonly used antimalarials, increasing global 
travel and global warming all suggest that the impact of malaria on the world is likely 
to rise. Malaria is now reappearing in some countries in which it had previously been 
eliminated.26 
Malaria in humans is caused by four species of Plasmodium protozoa: P. vivax, P. 
falciparum, P. malariae and P. ovale of which the first two are the most common. 
The parasites are transmitted by the bite of the female Anopheles mosquito. Nearly all 
deaths caused by malaria are due to infection by P. falciparum and this species 
develops drug resistant strains at a tremendous rate.  
Plasmodia undergo several morphological changes in both the human and mosquito 
host, see Figure 8. As she feeds on an infected person, the mosquito ingests parasites 
in the form of gametocytes. While in the mosquito’s stomach, the parasites reproduce 
to generate sporozoites, which travel to the insect’s salivary glands. During the next 
feeding, the victim is infected by the sporozoites. In the bloodstream, the parasites 
make their way to the liver, where they reproduce to generate thousands of 
merozoites, which pass back into the blood and infect erythrocytes (red blood cells). 
The merozoites digest host haemoglobin and plasma and generate more merozoites, 
each of which is capable of invading a new red blood cell. The infected erythrocytes 
lyse, releasing new merozoites as well as toxins and erythrocyte debris into the 
bloodstream. This sudden release of exogenous products induces the chills and fever 
so characteristic of malaria.27  
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Figure 8. Life cycle of the malaria parasite. Not all plasmodia generate hypnozoites.  
Malaria parasites can reproduce in the body at a phenomenal rate. Destruction of 94% 
of the parasites every 48 hours will only maintain status quo, and will not reduce their 
number or their ability to proliferate.28 Occasionally, merozoites generate 
gametocytes that are ingested by another mosquito. In some forms of malaria, the 
sporozoites on entering the liver cells form dormant hypnozoites (also termed 
“secondary schizonts”), which may liberate merozoites at a later stage several 
months, or even years, after initial infection. 
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1.4.1 Antimalarial natural products 
The majority of drugs used against malaria today have been developed from natural 
products. The oldest and still-used drug quinine (7) is obtained from the bark of the 
Cinchona-tree. The structure of quinine was established in 190829 and it has been the 
template for numerous other synthetic quinoline antimalarials with fewer side effects, 
such as chloroquine (8), primaquine (9), and mefloquine (10).  
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Figure 9. Quinine (7) and quinoline antimalarials 
In 1972, artemisinin (11) was isolated from Artemisia annua, an ancient Chinese herb 
used for malaria therapy, and identified as the active compound. Today, synthetic 
derivatives artemether (12a) and sodium artesunate (12b) are being used in clinical 
treatment of the infection. 
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Figure 10. Artemisinin (11) and synthetic derivatives 12a and 12b 
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Extracts of the leaves of Eucalyptus robusta are used in Chinese herbal medicine for 
the treatment of dysentery, malaria, and bacterial diseases. In 1984, three compounds 
with antimalarial activity were isolated from the extract: robustaol A (13) and 
robustadial A and B (2), of which the latter two had considerably greater activity than 
substance 13.20 
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Figure 11. Robustaol A 
The antimalarial activity of chalcones was first noted in 1994, when licochalcone A 
(14), a natural product isolated from Chinese liquorice roots, was reported to exhibit 
potent in vitro and in vivo antimalarial activity.30 Since then, a large number of 
chalcones and their derivatives have been synthesized and evaluated for activity 
against Plasmodia.19,23 An analogue of licochalcone A, 1-(4-butoxyphenyl)-3-(2,4-
dimethoxyphenyl)-2-propen-1-one (15), exhibited potent antimalarial activity.31 A 
drug design study reported 1-(2,5-dichlorophenyl)-3-(quinolin-4-yl)-2-propen-1-one 
(16) to be the most active of over 200 chalcone derivatives.23 The structures are 
depicted in Figure 12. 
O
HO OH
OCH3
H3C
H3C
CH2
14
O
O OH
OH
15
OCl
N
16
H3C
Cl
 
Figure 12. Chalcones with antimalarial activity 
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Biflavanone 17, isolated from an Arabic traditional medicinal plant, has shown 
moderate activity against P. falciparum.32 
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Figure 13. (2S,2''S)-7,7''-di-O-methyltetrahydroamentoflavone 
1.4.2 Antimalarials – current chemotherapy 
The specific mechanisms of current drug therapies in inhibiting malaria parasite 
growth are not known. Their modes of action are often complex, involving several 
different targets. Most antimalarial drugs act primarily at the erythrocytic stage of the 
parasite life cycle. The so-called blood schizonticidal agents (Figure 14, I) can cure 
infection caused by parasites that do not produce hypnozoites.   
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Figure 14. The sites of action (I-IV) of antimalarial drugs. 
Inhibition of haem polymerisation, through different mechanisms, is believed to be 
the mode of action of the quinoline antimalarials 7, 8 and 10 and artemisinin (11). 
The haem remaining after the parasites digest host haemoglobin is toxic to the 
parasites, which convert the haem to polymeric haemozoin. Inhibition of haemozoin 
formation will eventually kill the parasite.  
Primaquine (9) is active against the parasites in the liver, hence the term tissue 
schizonticidal agent (Figure 14, II). This drug effects cure of parasites having an 
exoerythrocytic stage.  
Drugs used for chemoprophylaxis (Figure 14, III) act on the merozoites when they 
emerge from the liver and prevent the development of malarial attacks. Drugs used 
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for this purpose are chloroquine (8), mefloquine (10), proguanil (18), pyrimethamine 
(19), dapsone (20) and doxycyline (21).  
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Figure 15. Structures of several widely used drugs in antimalarial chemotherapy 
Drugs 18-21 and sulphadoxine (22) all inhibit, by different mechanisms, metabolic 
pathways and precursors essential for the growth of the plasmodia.  
Primaquine (9), proguanil (18) and pyrimethamine (19) destroy gametocytes (Figure 
14, IV), thus reducing the spread of infection, but they are rarely used for this action 
alone. 
Treatment of malaria infection usually involves combinations of drugs with different 
mechanisms of action. This hinders the development of drug resistance in the 
parasite, and many compounds exhibit synergistic effects when combined. 
Atovaquone (23) is ineffective against malaria parasites alone, but is effective in 
combination with proguanil (18). Artemether (12a) is frequently administered in 
combination with lumefantrin (24). 
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Figure 16. Atovaquone (23) is only active in combination with proguanil (18). Lumefantrine 
(24) synergises  with artemether (12a). 
Some compounds, of which pyronaridine (25) holds most promise, are under clinical 
development. Pyronaridine inhibits DNA topoisomerase, an enzyme involved in the 
replication of DNA.33  
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Figure 17. Pyronaridine (25) is being evaluated in clinical trials. 
A number of novel potential targets have been identified, of which a few are 
inhibitors of phospatidylcholine biosynthesis, which is required for the growth of the 
parasite34 and others are inhibitors of parasitic proteases, which it uses to digest host 
haemoglobin. Chalcones are thought to act through inhibition of proteases, 
preventing haemoglobin degradation.23  
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Advances in genomics, including the elucidation of the complete genome sequence of 
the Anopheles mosquito and the parasite P. falciparum, offer promising new 
approaches for drug and vaccine development.35 
Mode of action of artemisinin (11) 
The mechanisms of action of artemisinin (11) are worth special mentioning. Several 
theories on the mechanisms of the compound and its derivatives have been postulated 
in numerous articles.36 The compound contains a unique 1,2,4-trioxane structure, in 
which the endoperoxide bridge appears to be necessary for antimalarial activity. 
Since reactive oxygen species such as hydroxyl radicals and superoxide are generated 
from peroxides, it has been suggested that free radicals might be involved in the 
antimalarial mechanism. It has been shown that artemisinin interacts with 
intraparasitic heme or iron, maybe causing the endoperoxide bridge to break open and 
form free radicals. Once formed, the artemisinin-derived free radicals attack vital 
targets in the parasite, most likely through alkylation of specific malaria proteins. 
This might explain the parasite-killing action of the drug. 
1.5 Oxidation of biological molecules 
1.5.1 Free radicals 
Free radicals play an important part in phagocytosis, the production of some 
biologically essential compounds and possibly in cell signaling. At the same time, 
they may cause oxidative modification of biological molecules, leading to oxidative 
damage and eventually to various diseases.37 Lipids, proteins and DNA are the main 
targets of free radicals and reactive oxygen species (ROS). Above all, the 
polyunsaturated fatty acids and their esters are susceptible to radical attack and 
oxidation. Their oxidation, referred to as lipid peroxidation, has been extensively 
studied and the mechanisms are now fairly well understood. 
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Lipid peroxidation by non-enzymatic pathways may proceed either by free radical-
mediated or non-radical mechanisms. Lipid radicals (L•) are generated by both 
radical and non-radical initiators (Figure 18, I) during arachidonic acid metabolism, 
NO synthesis, cigarette smoking, UV-radiation and by reactive metabolites of some 
drugs. A bisallylic H atom is abstracted to give a pentadienyl radical, to which 
oxygen reacts rapidly to produce lipid peroxy radical (LOO•). The oxygen adds, not 
necessarily to the position from which H was removed in the first place, but to 
mesomeric adjacent radical sites owing to stabilization of the conjugated diene 
formed. The resulting peroxy radical reacts with bisallylic hydrogen on another 
polyunsaturated fatty acid, giving rise to the corresponding lipid hydroperoxide 
(LOOH) and generating further lipid peroxy radicals. LOOH can also break down to 
toxic secondary products such as unsaturated aldehydes.  
I IHLH + + L
LOO+L ROS
LH LOOH+ + LLOO
Initiation
Propagation
 
Figure 18. Lipid peroxidation. LH = lipid, I = initiator, L• = lipid radical, LOO• = lipid peroxy 
radical, LOOH =lipid hydroperoxide 
ROS such as superoxide radicals are generated in vivo to kill bacteria and other 
microorganisms by phagocytosis and are essential for defence against bacterial 
infections, but sometimes the production of such radicals might exceed the 
requirement. ROS and the products of lipid peroxidation can attack many key 
molecules, including enzymes, membrane lipids and DNA. Oxidative stress occurs 
when excessive amounts of highly reactive free radicals are produced, and is involved 
in the pathogenesis of both cancerous and cardiovascular diseases. 
Enzymatic defence mechanisms, such as superoxide dismutase and catalase, and 
antioxidants such as ascorbic acid (vitamin C), gluthatione and α-tocopherol (vitamin 
E) can trap the free radicals, thereby breaking the peroxidative cascade reaction and 
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preventing biological damage. The radical formed from α-tocopherol is stabilised 
through delocalisation over the aromatic ring structure, and forms non-radical 
products. The mechanism of action of α-tocopherol is illustrated in Figure 19. 
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Figure 19. The radical (R•) scavenging action of α-tocopherol and some of the resonance 
structures of the resulting α-tocopherol radical 
Free radical-mediated processes in biological systems have been extensively studied 
over the past years. These reactions have been implicated in several pathological 
conditions such as atherosclerosis, inflammatory conditions (rheumatoid arthritis), 
neurodegenerative disorders, asthma, psoriasis, malaria and various forms of cancer.38  
Table 1. Conditions associated with the action of free radicals 
Ischaemia and damage following reperfusion Alcohol-induced damage 
Inflammatory diseases    Ageing 
Degenerative diseases    Cigarette-smoking 
Damage caused by irradiation   Some forms of cancer 
Hyperchromatosis     Atherosclerosis 
 
 
Thus, radical scavengers of the pathogenic active radicals have potential as 
therapeutic agents in a wide variety of illnesses. The role and beneficial effects of 
antioxidants against such oxidative stress support this view. 
 17
  
1.5.2 15-Lipoxygenase 
Lipoxygenases comprise a family of enzymes capable of mediating oxidation of 
polyunsaturated fatty acids to the corresponding hydroperoxide and are important 
oxidants in vivo. These enzymes, in contrast to the products of free radical-mediated 
oxidation, give regio-, stereo- and enantio-specific hydroperoxides.39    
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Figure 20 The action of 15-lipoxygenase on a polyunsaturated fatty acid 
For example, mammalian 15-lipoxygenase (15-LO) oxidises arachidonic acid to give 
mainly 15(S)-5Z,8Z,11Z,13E-hydroperoxyeicosatetraenic acid (15-HPETE). Products 
of 15-LO are shown to be potent signal transduction modifiers and appear to 
influence the inflammatory responses. Production of the eicosanoid lipoxins requires 
the action of 15-LO, and evidence suggests that the enzyme also contributes to the 
oxidation of LDL and the development of atherosclerosis. 
In the human body, arachidonic acid as well as eicosapentanoic acid serve as 
precursors of the so-called eicosanoids, which are implicated in the control of many 
physiological prosesses. Free arachidonic acid is metabolised by several pathways: 
cyclooxygenase (COX) initiates the biosynthesis of prostaglandins and 
thromboxanes, while the lipoxygenases (5-,12- or 15-LO) initiate the synthesis of 
leukotrienes, lipoxins and other compounds, see Figure 21. 
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Figure 21 Arachidonic acid metabolism and generation of eicosanoids. Arachidonic acid is 
the precursor of many lipid mediators. The sites of action of some anti-inflammatory drugs 
are shown. 
1.6 Inflammation  
Many eicosanoids are associated with pro-inflammatory responses, and inhibiting the 
arachidonic acid metabolism has shown to be an effective means of reducing 
inflammation. Several drugs have been developed that modify the enzymatic 
pathways to lipid metabolites. Non-steroidal anti-inflammatory drugs (NSAIDs) and 
selective COX inhibitors (Figure 21, I) block the synthesis of prostaglandins and 
thromboxanes, reducing inflammatory responses. Anti-leukotrienes either reduce 
leukotriene synthesis by inhibiting 5-lipoxygenase (Figure 21 II), or antagonize the 
most relevant of their receptors (Figure 21, III) and are a relatively new class of anti-
asthma drugs. Lipoxins, contrary to the other eicosanoids, appear to have anti-
inflammatory effects, although their role in inflammatory responses needs further 
investigation.40 Antioxidants affecting the 15-LO pathway to lipid mediators might be 
of therapeutical use in asthma and other inflammatory reactions. 
 19
  
1.7 Atherosclerosis 
Low-density lipoprotein (LDL) transports lipids and cholesterol through the 
bloodstream and is essential to life, but excessive concentrations in plasma increase 
the risk of coronary artery disease. The cells that line the blood vessels bind LDL 
and, when activated, these cells generate free radicals and other factors which oxidise 
LDL.  
 
Figure 22. Mechanisms by which the oxidation of LDL may contribute to atherogenesis.41 
Oxidized LDL releases chemotactic factors that recruit circulating monocytes (I) and prevent 
resident macrophages from leaving the inner lining of the blood vessels (II). Enhanced rate 
of uptake of oxidized LDL by macrophages leads to the generation of foam cells (III). 
Endothelial injury occurs due to the cytotoxic factors released by oxidized LDL (IV). 
Oxidized LDL is cytotoxic, and may harm the cells lining the blood vessels. It is 
taken up by macrophages, forming foam cells, which migrate beneath the inner lining 
of the blood vessels. This subendothelial collection of foam cells and other cells 
comprises the “fatty streaks” indicative of atherosclerosis. They release factors that 
induce deposition of fibrous tissue and stiffening of the blood vessel walls, eventually 
forming a dense fibrotic plaque. Oxidized LDL appears to release factors stimulating 
platelet aggregation and development of thrombosis. The plaque may rupture, 
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releasing aggregatory mediators, and form a thrombus, which may interfere with the 
blood supply to various organs and tissues, resulting in impaired function. A portion 
of the thrombus may break away, forming an embolus, which lodges downstream, 
causing infarction.42 Atherosclerotic lesions develop over many decades and once 
symptoms occur, the disease has reached an advanced stage. Evidence suggests that 
15-LO contributes to the oxidation of LDL.43 Therefore, inhibitors of 15-LO might 
limit the progression of atherosclerosis.  
1.8 Project description 
In the present study a series of chalcone and chroman derivatives of the general 
structures depicted in Figure 23 were synthesized and tested for antimalarial activity, 
radical scavenging actions and 15-LO inhibition (antioxidants).   
O
OCH3
OCH3
R
H3CO
O
OH3CO
OCH3
OH3CO
OCH3
R R
CH3
CH3
 
Figure 23. General structures of the chalcone and chroman derivatives 
Chalcones 
The choice of alkoxylated substituents on the B ring (see Figure 3) was based on 
information obtained from literature on structure-activity relationships, and the 
feasibility of the synthesis was also taken into account. Hydroxylated compounds 
proved more difficult to work with due to the reactivity of the phenolic groups. 
Substituted benzene and alternative ring systems such as pyridine, quinoline, furan, 
thiophene and indole as ring A were synthesized and tested in order to provide more 
information on the structural requirements of the A ring for biological activities.  
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Chroman derivatives 
The 1,3-ketoxy structure of 5-alkoxylated chromanones may have Fe-chelating 
properties, producing both antioxidant and antimalarial effects. The ketone moiety 
was removed to provide information on whether this particular structural feature is 
important for activity. This might also provide some indications as to the lipophilic 
requirements for biological activity. 
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2. Results and Discussion 
2.1 Syntheses  
2.1.1 Friedel-Crafts reaction between phloroglucinol and cinnamic 
acid derivatives 
Our first aim was to synthesize a chalcone with hydroxyl substituents in the 2’,4’- 
and 6’-positions. This was attempted prepared by the Friedel-Crafts acylation 
reaction of phloroglucinol with α,β-unsaturated para-methylcinnamic acid, using an 
excess of Lewis acid catalyst. The reaction is outlined in Scheme 1. NMR analysis of 
the crude product showed that the reaction produced only minute amounts of the 
chalcone in a complex mixture, and consequently we chose another approach. 
OHHO
OH
H3C
O
OH O
OHHO
OH
CH3AlCl3
+ POCl3
0-5°C
 
Scheme 1  
Substituting the acid with the acid chloride and using different solvents, such as THF, 
DCM and ether, did not improve the outcome of the reaction. Reaction in THF 
solution did not provide the desired chalcone, but compound 4-chlorobutyl E-3-(4-
tolyl)-2-propenoate (26) was formed (Scheme 2). This occurred most probably by 
acid-catalyzed opening of the tetrahydrofuran ring to 4-chloro-1-butanol, which 
subsequently reacted with the acid chloride. 
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Scheme 2 
The structure of the product 26 was assigned based on the NMR, IR and MS data. 1H 
NMR spectra of the compound showed two doublets (J  16.0 Hz) at 7.6 and 6.4 ppm, 
respectively, indicating the presence of an olefinic double bond with an E 
configuration.44 The aromatic protons exhibit two doublets (J  8.0 Hz) of the same 
integral height in the range 7.4-7.1 ppm, characteristic for para-substituted benzene. 
The methyl substituent on the aromatic ring appears as a singlet at 2.4 ppm. The 
aliphatic protons α to ester and α to Cl give rise to triplets (J  6.0 Hz) at 4.2 and 3.6 
ppm, respectively, whereas the methylene protons between them are not well 
differentiated, and appear as a multiplet at 1.9 ppm. In the HH COSY diagram, 
coupling interactions can be seen between the methylene multiplet at 1.9 and both 
triplets, as well as between the methyl substituent and the protons on the benzene 
ring, the protons further upfield showing the strongest coupling.  
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The 13C NMR spectrum disclosed twelve chemically non-equivalent carbons, and the 
CH COSY spectrum reveals to which proton they are bonded. The signal at 21.4 ppm 
arises from the methyl group attached to the phenyl group, whereas the strong signals 
at 129.5 and 128.0 ppm constitute the methine carbons. The signals at 116.8 and 
144.8 ppm represent the olefinic carbons α and β to the carbonyl group, respectively. 
Four C atoms with shift values 26.1, 29.1, 44.4 and 63.5 ppm form the butyl chain, of 
which the latter two characterize the carbons α to ester and α to Cl. The carbon at 
167.0 ppm shows no connectivity to proton in the HC COSY diagram. This lack of 
HC connectivity and the high shift value confirm the presence of an ester group. No 
connectivity is observed for the carbon atoms resonating at 131.5 and 140.7 ppm. The 
DEPT spectra verify the carbon connectivity in structure 26.  
In the infrared spectrum a broad peak was observed in the region 3036-2850 cm-1, 
and a peak at 1703 cm-1 is due to an α,β-unsaturated carbonyl group. EI-MS showed 
a signal for the molecular ion at m/z=252 and 254 in a 3:1 relation, respectively, 
indicating that the molecule contains a Cl atom. The peak at m/z=162 lacks this 
isotopic relationship and corresponds to a fragment formed by cleavage α to the ester 
function. The strongest mass peak was at m/z=145, arising from fragmentation of the 
ester. The data strongly supports the predicted structure. 
 Protection of the hydroxyl moieties on phloroglucinol as methyl or 
tetrahydropyranyl ethers produced in both cases a mixture of mono-, di- and tri-
protected phloroglucinol, which were difficult to separate by flash chromatography. 
The same tendency was seen when benzyl bromide was used as protecting agent. 
Failure to achieve adequate yields of chalcone in a one-step reaction between 
phloroglucinol and cinnamic acid derivatives led us to try a different pathway for the 
preparation of chalcones. Due to the reactivity of the phenolic groups, and difficulties 
experience in protecting them, we concentrated our efforts on methoxylated 
phloroglucinol-based compounds. 
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2.1.2 Nucleophilic addition to C=O with acetylide anion 
Phenylacetylene reacted with NaH to generate the acetylide anion, followed by 
reaction with 2,4,6-trimethoxybenzaldehyde affording 1-(2,4,6-trimethoxyphenyl)-3-
phenyl-2-propyn-1-ol (27) in very low yield (< 2%). Using the same reagents, but 
heating the reaction, increased the yield to 30%, see Scheme 3. Replacing NaH with 
MeLi at -78°C, did not improve the outcome (13%).  
CH
OCH3H3CO
OCH3O
OH
OCH3H3CO
OCH3
27 (30%)
1) NaH, 0-5 °C
2) ∆ ,
 
Scheme 3 
The 1H NMR spectrum of the alkynol 27 showed two multiplets with integral levels 
in a ratio of 2:3 at aromatic shifts around 7.4 and 7.2 ppm, respectively, matching the 
five protons in the unsubstituted A ring. The aromatic protons in the trimethoxy 
substituted B ring appear as a singlet at 6.2 ppm, whereas the para-methoxy group 
gives rise to a singlet at 3.8 ppm. The protons in the ortho-methoxy groups cannot be 
differentiated from the alcoholic proton, and they appear together in a multiplet in the 
range 3.9-3.86 ppm. The doublet (J  11.3 Hz) at 6.0 ppm arises from the proton α to 
the alcohol. Coupling between the doublet at 6.0 ppm and part of the multiplet is 
observed in the HH COSY diagram.  
The thirteen chemically non-equivalent C atoms in structure 27 appear as thirteen 
distinctive signals in the 13C NMR spectrum. With the aid of the DEPT spectra and 
the HCCOSY and HCCOLOC diagrams, each peak signal can be assigned to specific 
carbon nuclei. There are six carbons lacking HC connectivity, of which those at 
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161.1, 158.3 and 110.6 ppm are from the substituted benzene B ring, and the signals 
at 90.5 and 82.6 ppm arise from the ethynyl carbons α and β to the alcohol, 
respectively. The last carbon not bonded to a proton connects the A ring to the 
propynol moiety and exhibits a signal at 123.4 ppm. Because of the symmetry, the A 
ring methine carbons give rise to three signals at 131.7, 128.0 and 127.9 ppm. The 
peaks at 55.9 and 55.3 ppm in relation 2:1 correspond to the ortho- and para-
methoxy substituents of the B ring, in that order, and the signal at 91.3 ppm arises 
from the methine groups on the same ring. The alcoholic carbon has a peak signal of 
56.6 ppm.  
In the infrared spectrum peaks were observed at 3545 (O-H) and 2258 cm-1 (C≡C). In 
the MS spectrum, the molecular ion appeared at m/z=298, and fragmentation ions at 
m/z=283 and 267 are apparently derived from loss of one and two methyl groups, 
respectively. The strong peak at m/z=168 results most likely from fragmentation of 
the bond between the alcoholic carbon and the ethynyl group. 
LiAlH4 reduction of compound 27 under thermodynamic control in THF afforded an 
α,β-unsaturated alcohol.45  Subsequent oxidation of the intermediate with MnO2 
furnished E-1-(2,4,6-trimethoxyphenyl)-3-phenyl-2-propen-1-one (28) as a complex 
mixture, see Scheme 4. Comparison of the 13C NMR spectrum and IR data of 
compounds 27 and 28 provides evidence for the reduction of the ethynyl group. 
Compound 28 shows no IR absorbance characteristic of a triple bond and the ethynyl 
13C signals that were observed for compound 27 are absent. The 13C spectrum shows 
a signal at 194.0 ppm, indicating the presence of a carbonyl carbon. The yields were 
not established since the products could not be isolated by column chromatography.  
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OCH3H3CO
OCH3OH
27
 
Scheme 4 
Although compound 28 was not purified, information regarding the structure can be 
deduced from the NMR spectrum of the crude product. The 1H NMR spectrum 
indicates the presence of an E-olefinic proton by a doublet, J  16.0 Hz, appearing at 
7.0 ppm. The aromatic protons and the methoxy substituents on the B ring give rise to 
a pattern similar to the one described for compound 27; a singlet at 6.15 ppm and two 
singlets in the region 3.7-4.0 ppm.  
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Scheme 5 
Nucleophilic addition of 4-methoxyphenylacetylene to 2,4,6-trimethoxybenzaldehyde 
with subsequent oxidation was attempted (Scheme 5). Oxidation of the crude product 
was carried out using either Dess Martin periodinane or MnO2 in CHCl3. Both 
reactions produced inseparable mixtures of compounds, which were discarded. 
In summary, nucleophilic addition of acetylide anions to the 2,4,6-
trimethoxybanzaldehyde provided products that were difficult to purify. High purity 
is an absolute prerequisite for compounds that are to be tested in biological assays, 
and consequently we chose a different strategy. 
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2.1.3 Synthesis of starting materials 
The following section describes Claisen-Schmidt condensation reactions involving 
either 2,4,6-trimethoxyacetophenone (29) or 2,4-dimethoxy-6-hydroxyacetophenone 
(30) as a starting material. 
Synthesis of 2,4,6-trimethoxyacetophenone (29) 
Compound 29 was synthesised in 31% yield by a Friedel-Crafts acylation of acetic 
anhydride with 1,3,5-trimethoxybenzene, according to Scheme 6. The NMR spectra 
of compound 29 were identical to the spectra of 2,4,6-trimethoxyacetophenone 
obtained from a commercial source. 
OCH3H3CO
OCH3
CH3
O
OCH3H3CO
OCH3
H3C O CH3
O O
H2SO4
29 (31%)
+
 
Scheme 6 
Synthesis of 2,4-dimethoxy-6-hydroxyacetophenone (30) 
The compound was obtained from a methylation reaction of phloroacetophenone with 
dimethyl sulphate46 in 68% yield as depicted in Scheme 7. The NMR data are 
identical to the NMR data taken of a commercially produced sample of compound 
30. 
OHH3CO
OCH3
CH3
O
OHHO
OH
30 (68%)
acetone
1) K2CO3
2) (CH3)2SO4, ∆
CH3
O
 
Scheme 7 
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2.1.4 Claisen-Schmidt condensation of trisubstituted 
acetophenone with aromatic aldehyde  
The Claisen-Schmidt condensation of aromatic aldehyde with a substituted 
acetophenone (29) in the presence of NaOH or KOH in protic solvent has frequently 
been used to synthesize chalcones in high yields. 
CH3
O
OCH3
OCH3
R
O
O
OCH3H3CO
OCH3
R
+
NaOH
EtOH
28,31-54 (8-90%)
H3CO
 
Scheme 8 
A variety of chalcone derivatives (28,31-54) was synthesized in this manner (Scheme 
8), see Figure 24 and Table 2. Yields range from 8% to 90%, but were not optimised. 
All the compounds were crystalline, their colours ranging from creamy white through 
yellow to orange, except for E-1-(2,4,6-trimethoxyphenyl)-3-(pyridin-4-yl)-2-propen-
1-one (47) which was a yellow oil. A search of the literature revealed different 
melting point values for chalcone 47: 101-10347 and 8048 °C. Polymorphism has been 
reported for many chalcones, and this may explain some of the discrepancies 
observed between our melting points and the values reported in the literature.49  
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Figure 24 Structures of chalcone derivatives 
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Table 2 Chalcone derivatives prepared in this study 
Nr R2 R3 R4 R5 R6 Formula Yield (%) 
 
28 H H H H H   C18H18O4    76 
31 NO2 H H H H   C18H17NO6    82 
32 H NO2 H H H   C18H17NO6    87 
33 H H NO2 H H   C18H17NO6    87 
34 Br H H H H   C18H17BrO4    80 
35 H H Br H H   C18H17BrO4    63 
36 H H CH3 H H   C19H20O4    80 
37 H H t-Bu H H   C22H26O4    55 
38 H H OCH3 H H   C19H20O5    58 
39 OCH3 OCH3 OCH3 H H   C21H24O7    70 
40 OCH3 H OCH3 OCH3 H   C21H24O7    50 
41 OCH3 H OCH3 H OCH3   C21H24O7      8 
42 H OCH3 OCH3 OCH3 H   C21H24O7    70 
43 H H OH H H   C18H18O5    30a 
44 H OH OH H H   C18H18O6    14a 
45 - - - - -   C17H17NO4      25 
46 - - - - -   C17H17NO4    48 
47 - - - - -   C17H17NO4    40 
48 - - - - -   C21H19NO4    75 
49 - - - - -   C21H19NO4    85 
50 - - - - -   C21H19NO4    85 
51 - - - - -   C20H19NO4  n.d.b 
52 - - - - -   C20H19NO4    19 
53 - - - - -   C16H16SO4    72 
54 - - - - -   C16H16O5    36 
a Over two steps  b Not determined 
 
The structures of the compounds 28 and 31-54 were confirmed by NMR, MS and, 
occasionally, IR analysis. The 1H NMR spectra for the compounds had several proton 
signals in common. The aromatic protons at C-3’ and C-5’ appear as a singlet around 
6.3-6.0 ppm, whereas the three methoxyl groups of the same ring B give rise to two 
singlets in the integral ratio 6:3 at 4.0-3.7 ppm. The olefinic protons give rise to two 
doublets (J  ca. 16 ppm), α-H in the range 7.3-6.7 and β-H in the range 8.1-7.1 ppm. 
The α proton appears further upfield compared to the β proton due to the shielding 
effect of the carbonyl group. The coupling constant of 16 ppm strongly indicates that 
the protons have a trans configuration, which is consistent with the observation that 
the more stable trans isomers are produced in the synthesis of chalcones.50  
 33
  
The 13C NMR spectra also demonstrate some common features. The carbonyl carbon 
appears at the low field of 197-192 ppm. The aromatic C-3’ and C-5’ of the 
trimethoxylated B ring provide a signal at 92-90 ppm, while the methoxy carbons 
give rise to two peaks in the range 57-55 ppm with a ratio of 2:1.  
The 1H NMR signals arising from the A ring differ in chemical shifts, caused by the 
different shielding effects of the varying substituents and ring structures. In the case 
of the unsubstituted benzene ring A in compound 28, five H atoms usually appear as 
three signals, due to magnetic equivalence of protons at C-2 and C-3 with C-6 and C-
5, respectively. In our case, the signals of C-3, C-4 and C-5 were not differentiated, 
and gave rise to a multiplet together with the olefinic α proton. A similar 
phenomenon is observed for symmetrically substituted A rings such as the 4-
monosubstituted chalcones 33, 35-38 and 43, the 2,4,6-trisubstituted chalcone 41, the 
3,4,5-trisubstituted compound 42, as well as for the pyridin-4-yl 47. The signals due 
to the A ring protons appear in the range 6.0-9.1 ppm, of which the highest chemical 
shifts are observed for the protons of heterocyclic compounds containing shielding N 
atom. Electron-rich substituents such as the nitro group also shift the proton signals 
further downfield due to their shielding effect.  
The 13C NMR spectral analysis of 2’,4’,6’-trimethoxychalcone 28 displays the 
expected thirteen signals corresponding to the eighteen carbon atoms. Chalcones with 
symmetrically substituted A rings also display only thirteen peaks in their 13C NMR 
spectra, caused by the chalcone nucleus. In the presence of  an unsymmetrical ring, 
all the A ring carbons display distinct signals in addition to the carbon-containing 
functional groups. 
MS analyses were performed on all structures, except the indole derivatives 51 and 
52 because of their instability. For HRMS mass determination, deviations were less 
than 5 ppm. In EIMS, all compounds exhibited a fragment at 195, corresponding to 
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cleavage of the bond between the carbonyl group and the double bond, providing a 
trimethoxybenzaldehyde ion, see Figure 25.  
O
R
OCH3H3CO
OCH3 O
OCH3H3CO
OCH3
 
Figure 25 The fragmentation ion (m/z=195) of chalcone derivatives 25 and 31-54 
Br-substituted compounds 34 and 35 showed characteristic Br-peaks in 1:1 relation at 
[M+] and [M++2]. The chalcones 31-33 showed characteristic IR absorption 
frequencies for the nitro group around 1510-1565 and 1345-1385 cm-1.  
Condensation of 2,4,6-trimethoxyacetophenone (29) with indolecarboxaldehydes 
provided the unstable indole A ring products 51 and 52. E-1-(2,4,6-
Trimethoxyphenyl)-3-(3-indolyl)-2-propen-1-one (51) was obtained in a very low 
yield and was difficult to purify by flash chromatography, and thus was not isolated 
and the yield has not been determined. Due to their instability, the indole derivatives 
51 and 52 were not used in further reactions or subjected to any biological tests. 
Some aldehyde derivatives do not undergo reaction by the Claisen-Schmidt pathway. 
3-Methoxyfuraldehyde did not undergo condensation at all. This might be explained 
by the electron-donating properties of the methoxy substituent, which might promote 
cleavage of the furan ring.  
Claisen-Schmidt reaction of 2,4,6-trimethoxyacetophenone (29) with hydroxy-
substituted benzaldehydes proved difficult and protection of the hydroxyl groups was 
required. This observation is supported by earlier findings that the reactivity of the 
carbonyl carbon in para-hydroxybenzaldehyde is lowered in alkaline medium.51 This 
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lower reactivity of the carbonyl carbon has been explained by the delocalisation of 
the negative charge on the phenolic oxygen (Figure 26).   
HO
O
O
O
H +
O
O
 
Figure 26 Delocalization of negative charge in phenolic benzaldehyde 
Following protection of the hydroxyl moieties on the aldehyde with THP, reaction 
with substituted acetophenone and subsequent removal of the protecting groups by 
acid hydrolysis gave the chalcones 43 and 44 in overall yields of 30 and 14%, 
respectively. The reaction sequence is shown in Scheme 9. Protection with other 
groups, such as acetyl and TMS was attempted, but with poor results. 
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Scheme 9 
 
Thermally induced Claisen-Schmidt condensation of 2,4-dimethoxy-6-
hydroxyacetophenone (30) with various substituted aldehydes afforded in only one 
case the pure 2’,4’-dimethoxy-6’-hydroxychalcone derivative 55, while in others the 
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corresponding chromanones were formed, see 56-58, Scheme 10. Clearly, the 6’-
hydroxy substituent promotes the cyclization. Furthermore, in the reaction of 
compound 30 with 2,4,6-trimethoxybenzaldehyde, NMR data of the product suggests 
that a mixture of the corresponding chromanone and the 2’,4’-dimethoxy-6’-
hydroxychalcone was formed. For further information on the cyclized products 56-
58, see section 2.1.5. 
O
OCH3H3CO
OH O O
OH3CO
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R
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+
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OCH3H3CO
OH
O
N
+
NaOH 
EtOH, ∆
O
OCH3H3CO
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Scheme 10 
 
Due to extremely poor solubility, the structure of E-1-(2,4-dimethoxy-6-
hydroxyphenyl)-3-(quinolin-4-yl)-2-propen-1-one (55) has been assigned based 
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solely on the 1H NMR and MS data. The 1H NMR spectrum, in deuterated MeOH at 
50 °C, indicates the presence of thirteen non-equivalent protons, which is consistent 
with the predicted structure. The B ring is, unlike the chalcone derivatives 28 and 31-
54, not symmetrical. Therefore, the aromatic protons in compound 55 give rise to two 
signals: doublets (J  2.3 Hz) at 6.05 and 6.00 ppm, the proton at C-3’ position giving 
rise to the higher shift value due to the shielding 2’-hydroxyl moiety. The methoxy 
protons appear as singlets at 3.81 and 3.71 ppm. The five protons on the quinoline 
ring provide peaks in the region 7-9 ppm, but the information supplied by the spectral 
data is not sufficient to assign a particular proton to a specific signal. The same 
applies to the olefinic protons of the α,β-unsaturated ketone and the hydroxyl proton 
on the B ring. In the EIMS the mass at m/z=335 corresponds to the molecular ion M+, 
while the mass at 353 most likely arises from [M++H2O]. The major peak appears at 
m/z=181, which is analogous to the characteristic fragmentation previously observed 
for all the 2’,4’,6’-trimethoxychalcones (Figure 25). 
No reaction occurred between 2,4-dimethoxy-6-hydroxyacetophenone (30) and the 
pyridinyl aldehydes. 
The Claisen-Schmidt reaction between a tri-substituted acetophenone and a 
substituted benzaldehyde proved to be the most efficient method of chalcone 
synthesis, providing products that were easily purified. 
2.1.5 Cyclization: chalcones to chromanones 
The ring closure of chalcones to chromanones requires a hydroxyl moiety in C-2’ of 
the chalcone.52 The majority of our chalcone derivatives were 2’,4’,6’-
trimethoxysubstituted chalcones and therefore selective demethylation to provide a 
2’-hydroxychalcone had to be performed prior to cyclization. Search of the literature 
provided us with several pathways for such a demethylation.  
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The first method involved BBr3, which has been reported to demethylate a flavanone 
at the 5-position.53 The reaction of E-1-(2,4,6-trimethoxyphenyl)-3-(quinolin-4-yl)-2-
propen-1-one (50) with BBr3 afforded the chromanone 59 in 57% yield, see Scheme 
11. Cyclization was unexpected and occurred most likely during the work-up 
procedure, which involved trituration with boiling 50% EtOH to remove remaining 
BBr3 that might have complexed with the heteroatom in the quinoline structure.  
BBr3
DCM
O
OCH3H3CO
OCH3
N
O
OH3CO
OCH3
N
50% EtOH
∆
59 (57%)50
 
Scheme 11 
NMR analysis of compound 59 supports the chromanone structure. Chromanones 
have some common, distinctive features in their 1H NMR spectra. The proton at C-2 
appears as a doublet of doublets (J ca. 13 Hz trans, J ca. 3 Hz cis) centered at about 
5.3-5.0 ppm. The protons at C-3 also give rise to doublets of doublets at 4.0-2.5 ppm 
due to coupling with each other (J  ca. 16 Hz) and with the proton at C-2. As was the 
case for the 2’-hydroxy chalcone derivatives mentioned previously, there is no 
symmetry in the aromatic ring, and the aromatic A ring protons exhibit two distinct 
signals. The proton NMR spectrum of chromanone 59 shows all these characteristics. 
The six protons of the quinoline structure give rise to several signals between 9.0-7.9 
ppm, whereas the protons of the methoxy substituents appear together with a proton 
from C-3, as a multiplet at 3.8-3.7 ppm.  
Due to very poor solubility of compound 59, 13C NMR and 2-D analysis could not be 
performed. Increasing the probe temperature to 50 °C did not improve the solubility. 
MS analysis revealed the molecular ion at m/z=335 and relatively strong peaks at 
m/z=207 and 143. Bond breakage between the quinolinyl moiety and the bicyclic 
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system most likely gives rise to the observed fragment at m/z=207. The melting point 
could not be determined as the compound decomposed upon heating. 
Another method reported the use of AlCl3 for demethylation of chalcone 60 in 91% 
yield,54 but did not specify the use of solvent for the reaction. Our first endeavour was 
with 1,2-dichloroethane as solvent, affording E-1-(2,4-dimethoxy-6-hydroxyphenyl)-
3-(4-methoxyphenyl)-2-propen-1-one (60) in only 3% yield. Correspondence with 
the author provided us with the correct solvent, and dichloromethane was indeed a 
better option; furnishing the chalcone 60 in 28% yield, see Scheme 12. This is a poor 
result compared to the yield stated in the literature, and is most likely caused by the 
work up process, which we did not optimise. The structure of compound 60 was 
ascertained by comparison of the spectral data with those published.  
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Scheme 12 
Demethylation to E-1-(2,4-dimethoxy-6-hydroxyphenyl)-3-(4-methoxyphenyl)-2-
propen-1-one (60)  produces an unsymmetrical B ring, giving rise to a signal pattern 
similar to that of the B ring in 2’,4’-dimethoxy-6’-hydroxychalcone 55. A singlet at 
14.41 ppm in the 1H NMR spectrum represents the 6’-hydroxy substituent, the high 
chemical shift value indicates that it is most likely hydrogen-bonded. This is 
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supported by the broad IR absorption band displayed at 3584 cm-1, characteristic of a 
hydrogen-bonded hydroxyl group. Apart from the data of ring B, the NMR spectra 
exhibit the same features as the trimethoxy chalcones (see 2.1.4). MS data revealed 
the highest peak at m/z=314 to be M+, the fragments at m/z=207 and 180 are the 
same as those observed for compounds 59 and 55, respectively. Further cyclization of 
the chalcone 60 to a chromone with I2/pyridine54 failed to provide the desired 
product. 
The chromanones are isomeric with the chalcones and are obtained from the latter by 
acid- or base-catalysed ring closure. Thermally induced cyclization of chalcone 55 
with K2CO3 in EtOH did not provide the desired products (Scheme 13). Instead, the 
reaction afforded an inseparable mixture that was poorly soluble in common reagents 
such as CHCl3, DMSO, acetone, hexane and MeOH, and the complexes did not move 
on a TLC plate.  
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Scheme 13 
A literature search revealed that high-yield synthesis of 5-hydroxyflavanone could be 
carried out using a NiCl2-Zn-KI reagent system without prior demethylation,55 see 
Scheme 14. The experimental procedure was followed, but no reaction was observed. 
Lack of time prevented us from investigating this further.  
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Scheme 14 
The chromanone structures of 56-58 (Scheme 10) were established by NMR and MS. 
The 1H NMR spectra show the characteristic chromanone signals mentioned for 
compound 59. The B ring of chromanone 56 is an unsubstituted phenyl, and the 
protons appear as a multiplet at 7.36-7.20 ppm. Para-substitution on the A rings of 
chromanones 57 and 58 provides symmetry, thus the aromatic protons give rise to 
two distinct doublets (J  8.6-8.7 Hz) in the range 7.4-6.9 ppm. The methoxyl group 
on the A ring of compound 58 is presented by a singlet in the methoxyl region, 
whereas the tert-butyl group of compound 57 produces a singlet at 1.28 ppm. This is 
supported by the 13C NMR spectra, which show the same number of peaks as the 
number of magnetically non-equivalent carbon atoms. In the 13C NMR peaks for 
chromanones, signals due to the C-2 and C-3 carbons of the C ring appear at about 80 
and 45 ppm, respectively.  
Two additional protons are observed in the 1H NMR spectrum of chroman 58: a 
singlet at 13.74 ppm and a signal within the multiplet at 3.44-3.28 ppm, both with 
integral ratios of 1:1. The lowfield chemical shift of around 14 ppm is most likely 
from a H-bonded hydroxyl group, and the signals were thought to arise from a 
hydrate. The compound was dried in a vacuum oven over five days, but still the 
signals persisted. The MS data do not show any sign of a hydrate, but revealed the 
molecular ion at m/z=314. The same 1H NMR signals were observed for a similar 
chroman derivative in which the methoxyl group was replaced by a nitro group. 
Unfortunately, the nitro compound was hard to isolate by flash chromatography, and 
we did not pursue this any further.  
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Chromanones have been synthesised by several pathways. The best results were 
obtained with BBr3, furnishing a 57% yield of the chromanone 59. Compounds 56-58 
were obtained in 1-20% yields by spontaneous cyclization, see 2.1.4, owing to the 
hydroxyl substituent in the 2’-position. Cyclization of chalcones to chromanones 
seems to occur during work-up procedures, as has been suggested for the reaction of 
59. 
2.1.6 Synthesis of chroman derivatives 
To evaluate the importance of the carbonyl group in relation to biological activity, 
compounds with this structural feature replaced were prepared. Alkylsubstituted 
chroman derivatives have been reported previously.56 The reaction involved 
alkylation with methallylzinc bromide, followed by acid treatment and catalytic 
hydrogenation to provide good yields of polycylic chromans, see Scheme 15. 
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Scheme 15 
 With this in mind, we attempted to alkylate our chromanones 56 and 57 using a 
similar reaction sequence without the additional dehydrogenation step of the 
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intermediate. Reactions with isobutylmagnesium bromide furnished the 
corresponding homoallylic alcohols 61 and 62 in 61% and 52% yields, respectively 
(Scheme 16). 
 
O
OH3CO
OCH3
OH3CO
H3CO
i-BuMgBr
THF
-10 to -5°C HO
61 R=H (61%)
62 R=t-Bu (52%)
56 R=H
57 R=t-Bu
R R
OH3CO
OCH3
R
H2/Pd-C
63 R=H 
64 R=t-Bu  
Scheme 16 
Intermediates 61 and 62 were purified and their structures established by NMR. Both 
compounds contain two stereogenic centres, at C-2 and C-4. The signal pattern for 
the protons of the methoxyl groups in compound 62 indicate that the alcohol was 
obtained as a mixture of diatereomers, in a 1:5 ratio (see Figure 27). This feature was 
not observed for chroman 61, suggesting that it was obtained in higher diasteromeric 
purity. The 13C NMR spectrum of chroman 62 is complex and exhibits multiple 
signals for many of the carbon atoms owing to the stereogenic centre. 
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Figure 27. Extract from the 1H NMR spectrum of (±)-2-(4-tert-Butylphenyl)-4-isobutyl-5,7-
dimethoxy-chroman-4-ol (62). The methoxy protons in the diastereomers appear at 
differentiable chemical shifts 
Chroman-4-ols 61 and 62 were subjected to the last step of Scheme 16, catalytic 
hydrogenation, to provide chromans 63 and 64, respectively. Compound 63 exhibits a 
slightly different 1H and 13C NMR signal pattern than its corresponding chromanol 
61. In the 13C NMR spectra, the C-4 signal at 71.48 ppm for the chromanol 61 has 
been replaced by a signal at 21.01 ppm for compound 63, suggesting that reduction 
has taken place. Furthermore, the singlet at 4.14 ppm of the 1H spectrum representing 
the hydroxyl proton of the chromanol is absent in the spectrum of compound 63. The 
1H and 13C NMR spectra of chroman 64 displayed a large number of signals, owing 
to its chirality, and they have not been interpreted. Lack of time prevented us from 
purifying the products, thus the yields were not established.  
No reaction was observed in an attempt to alkylate 5,7-dimethoxy-2-(quinolin-4-yl)-
chroman-4-one (59). Heating the reaction mixture of chromanone 59 and 
allylmagnesium bromide did not promote alkylation, suggesting that the quinoline 
structure somehow deactivates the organometallic compound. 
In summary, four chroman derivatives were synthesized, giving stereoisomeric 
products of varying diastereomeric ratio.  
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2.1.7 Carbonyl olefination 
The antimalarial activity of artemisinin has been related to the presence of an 
endoperoxide bridge in its structure (see pg. 15). Recently, antimalarial activity has 
been reported for cyclic peroxy ketals (65).57 Inspired by this evidence, we wanted to 
attempt a synthesis of a structurally similar dioxine, starting with our conjugated 
enones. After olefination, oxygenation of the diene function should provide a 1,2-
dioxine, see Scheme 17. 
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Scheme 17 
Olefination of the carbonyl group proved difficult. E-1-(2,4,6-trimethoxyphenyl)-3-
phenyl-2-propen-1-one (28) was reacted with methylene triphenylphosphorane in a 
classical Wittig reaction under various conditions, but failed to produce the olefin, 
probably due to steric effects. Instead, to our surprise, we isolated compound 34, see 
Scheme 18. Ortho lithiation is known to occur on phenyl rings bearing an electron-
rich substituent.58 
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Scheme 18 
Methylenation with trimethylsilylmagnesium bromide provides an alternative to the 
Wittig reagents. Although the alkylsilyl Grignard reagent is sterically demanding, it is 
known to react with sterically hindered ketones when a Wittig reagent fails, 
producing a β-hydroxysilane intermediate. Forcing conditions (KH, THF, 150°C) 
were used to effect elimination of H2O.59  This provided us with the compound 66 as 
part of a complex mixture (Scheme 19).  
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Scheme 19 
The 1H NMR spectrum of compound 66 indicates that olefination has occurred, but a 
great deal of unreacted intermediate remains. The compounds were difficult to isolate 
by flash chromatography, thus the yields were not established. 
Methylenation has also been achieved by reaction of carbonyl with lithium alkyls and 
aryls, followed by elimination of water.60 Reaction of E-1-(2,4,6-trimethoxyphenyl)-
3-phenyl-2-propen-1-one (28) with methyl lithium, followed by treatment with acid 
(March, p. 920.) gave the 1,4-adduct 67 and not the anticipated 1,2-adduct, see 
Scheme 20. 
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Scheme 20 
The structure of the substituted butanone 67 was established with the aid of NMR and 
MS. A similar NMR signal pattern to that for the chalcone derivatives in section 2.1.4 
was observed for the trimethoxy substituted B ring. In addition, a multiplet at 7.26-
7.13 ppm occurred for the five protons on the unsubstituted phenyl A ring. There 
were no olefinic protons present and a doublet (J 6.9 Hz) with an integral ratio of 3 
appears at 1.30 ppm, representing the methyl group. This was supported by the 
observation of a characteristic peak at 21.88 ppm in the 13C NMR spectrum. The 
proton on C-3 of the butanone gives rise to a multiplet at 3.54-3.38 ppm as it couples 
with the C-4 methyl protons and the methylene protons at C-2, whereas the latter 
contribute two distinct doublets of doublets (J  16.6 Hz geminal coupling, J  5.6 and 
8.7 Hz vicinal coupling). In the EIMS a small signal for the molecular ion at m/z=314 
is present, whereas the peaks of highest intensity are observed at m/z=297 and 195; 
the former corresponds to a demethylation of the compound 67 while the latter is due 
to a fragmentation characteristic for our chalcone derivatives, see section 2.1.4. 
Our attempts to olefinate the α,β-unsaturated carbonyl group were not successful. 
Most likely, the ketone moiety is too sterically hindered for reaction with Wittig 
reagents. Peterson olefination provided a complex mixture of compounds. Reaction 
with alkyl lithium produced the 1,4-Michael adduct and not the desired 1,2-adduct.
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2.2 Antimalarial activity 
2.2.1 Structure-activity relationships of robustadial 
As part of the work of the Skattebøl group, a series of robustadial chroman and 
chromanone analogues were synthesised and assessed for their antimalarial activity, 
providing information on the relationship between chemical structure and biological 
activity.24  
OR3O
OR3
R2
R1
R4
R4
O
OR3O
OR3
R2
R1
R4
R4
R1 and R2 =  alkyl
R3 = H,CH3
R4 = H,CHO
 
Figure 28. Structures of various chroman and chroman-4-one analogues of robustadial 
Analogues without formyl groups on the phenyl ring show only slight changes in 
activity when compared to their aldehyde counterparts, implying that the aldehyde 
group is not important for activity. The chroman derivatives possess higher activity 
than the chromanone derivatives, indicating that the lipophilic properties of the 
molecule influence activity. This is supported by the observation that the 
hydroxylated compounds had slightly higher antimalarial activity than their 
methoxylated analogues. Comparison of structures with various substitution patterns 
at C-2 showed that the size of the alkyl groups R1 and R2 influence activity. 
Structures with spiro constellation of ring sizes n > 6 had low antimalarial activity 
compared to compounds with smaller substituents at C-2. Attachment of substituted 
phenyl groups at C-2 of the chromanones did not improve activity, neither did 
replacement of the phenyl group with thiophenyl or furanyl rings. 
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2.2.2 Chalcones 
Very few studies on structure-activity relationships of antimalarial chalcones have 
been reported. Results from screening of more than 200 chalcone derivatives, 
revealed that (i) chalcones having electron-donating substitution on the B ring and 
electron-withdrawing substituents on the A ring, are associated with good 
antimalarial activity, (ii) both chloro-substituted and non-substituted quinolinyl 
groups as the A ring yield compounds with good activity no matter which 
substitution pattern was displayed on the B ring, (iii) di- and trimethoxy-substituted B 
ringS increase activity regardless of the substitution positions, and (iv) the α,β-
unsaturated ketone moiety is essential for activity in the series.19a,23 
2.2.3 Results  
The results from the biological testing are not available. 
2.3 Antioxidant properties 
2.3.1 Scavenging of DPPH radical 
Structure-activity relationship of flavonoids and chalcones as antioxidants 
A large number of antioxidants and radical scavengers have been reported in the 
literature. The flavonoids have received considerable attention in this respect, as they 
have potent antioxidant and radical scavenging properties. Studies on structure-
activity relationships of these compounds have shown that the presence of adjacent 
hydroxyl groups in the B ring of the flavonoid (3’,4’-OH) and hydroxyl groups at C-3 
and C-5 seems to promote radical scavenging activity. The double bond between C-2 
and C-3 also appears to contribute to the antioxidant activity.61 Phenolic hydroxyl 
 52
  
groups are likely to act as hydrogen donors in the scavenging of free radicals, and this 
might explain their importance for the activity, see below.  
The scavenging effects of chalcone derivatives on the diphenylpicrylhydrazine 
radical (DPPH•) are shown in Table 3. Only E-1-(2,4,6-Trimethoxyphenyl)-3-(3,4-
dihydroxyphenyl)-2-propen-1-one (44) showed significant activity. This is consistent 
with previous findings that chalcones with 3,4-dihydroxy substituted rings act as 
DPPH radical scavengers. The proposed reaction mechanism consists of hydrogen 
atom transfer from a phenol donor62 to give DPPH, thereby forming a phenoxyl 
radical. The radical is stabilised by delocalisation over the aromatic ring structure, see 
Figure 29. 
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Figure 29 Reaction of catecholic chalcone 44 with DPPH radical and resonance-
stabilisation of phenoxyl radical 
The chalcone structures bear many similarities to the flavonoid structures and it is not 
surprising that they show related structure-activity relationships. It has been proposed 
that hydroxy and methoxy substituents on both the A and B rings are essential for 
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antioxidant and radical scavenging activities of chalcone derivatives.63 The α,β-
double bond and a 2’-hydroxyl group also appear to be important for activity.16 
2.3.2 Inhibition of 15-LO 
15-LO from soybeans was used for the biological testing. It has been reported that 
there is a good correlation of inhibitory activity between this enzyme and mammalian 
15-LO, even though they are not identical.64 The enzyme oxidises linoleic acid, 
which serves as substrate in our study, to 13(S)-9Z,11E-hydroperoxyoctadienic acid, 
see Figure 30.65 
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Figure 30. Peroxidation of linoleic acid by 15-LO. 
The degree of formation of conjugated double bonds by the action of 15-LO on the 
substrate can be followed spectroscopically at 234 nm. The relative change in the 
absorbance of the solution  provides a measurement of the lipoxygenase-modulating 
effect of the test substance. 
All of the chalcone derivatives exhibited activity as enzyme inhibitors and IC50 values 
were determined. The inhibition was statistically significant (p<0.05) at 
concentrations of 75 µM for all substances, see Table 3. Highest activity was 
observed for compounds 35, 37, 41 and 48 with IC50 values of 55, 59, 43 and 56 µM, 
respectively. Most of the 15-LO inhibitors reported herein have IC50 values in the 
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range 40 to 140 µM. This compares favourably with 15-LO inhibiting effects of the 
natural product quercetin (68) (IC50 = 38 µM), which functions as the standard in this 
study. The data are insufficient to predict a rational structure-activity relationship for 
the 15-LO inhibitory action of the compounds. Earlier research has shown that the 
α,β-unsaturated ketone moiety is required for activity,47 which may be mediated by 
conjugate addition of a biological nucleophile to the chalcone.  
O
OH
OH
O
OH
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HO
68  
Figure 31 The structure of quercetin 
There are some test values missing because of difficulties in the experimental 
determination. Furthermore, certain compounds (31,33,38,53) gave less reproducible 
results due to poor solubility in the test solution.  
 55
  
 
Table 3. Scavenging of DPPH radical and inhibition of 15-lipoxygenase 
Nr A-ring  % DPPH• scavenging after 5 min Inhibition of 15-LO 
    (conc. 300 µM)  (conc. 75 µM)  IC50a 
 
28 C6H5    0.1 ± 0.3b    37 ± 5    91 ± 7 
31 2-NO2C6H4   0.9 ± 0.2    25 ± 5    142 ± 18c 
32 3-NO2C6H4   0.5 ± 0.2    22 ± 11   88 ± 5 
33 4-NO2C6H4   0.7 ± 0.3    34 ± 7    > 75c 
35 4-BrC6H4   0.6 ± 0.1    65 ± 3    55 ± 8 
37 4-t-BuC6H4   0.2 ± 0.1    62 ± 3    59 ± 5 
38 4-OCH3C6H4   0.3 ± 0.2    41 ± 3    > 75c 
39 2,3,4-(OCH3)3C6H2  0.4 ± 0.2    37 ± 8    110 ± 13 
40 2,4,5-(OCH3)3C6H2  0.4 ± 0.1    48 ± 9    78 ± 11 
41 2,4,6-(OCH3)3C6H2  0.4 ± 0.3    73 ± 1    43 ± 9 
42 3,4,5-(OCH3)3C6H2  0.3 ± 0.2    56 ± 3    67 ± 4 
43 4-OHC6H4   0.6 ± 0.1b    42 ± 5    87 ± 7 
44 3,4-OHC6H3   90.8 ± 0.1b    45 ± 4    81 ± 5 
45 pyridin-2-yl   0.2 ± 0.2    42 ± 3    86 ± 4 
46 pyridin-3-yl   0.1 ± 0.1    30 ± 2    107 ± 5 
47 pyridin-4-yl   0.2 ± 0.2    38 ± 4    91 ± 5 
48 quinolin-2-yl   0.3 ± 0.1    72 ± 4    56 ± 5 
53 2-tiophenyl   0.4 ± 0.1    30 ±3    114 ± 13c 
54 2-furanyl   5.3 ± 1.4    29 ± 6    109 ± 9 
68 -        n. d.d     84 ± 1    38 ± 2 
a Data are shown ± SD. b Concentration 150 µM. c Poor solubility. d Not determined. 
 
2.3.3 Conclusion 
Significant inhibition of the enzyme 15-LO was observed for all substances tested. 
No obvious correlation between enzyme inhibition and DPPH radical scavenging was 
observed. This lack of correlation indicates that the chalcones inhibit 15-LO by 
binding to the enzyme rather than by scavenging radicals arising from 15-LO 
oxidation of the fatty acid substrate. This is in accordance with previously reported 
results. Chalcones contain an electrophilic enone moiety and may act as alkylating 
agents. In view of the fact that the compounds have shown low activity as DPPH 
radical scavengers, they may be regarded as non-oxidant inhibitors of 15-LO.
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3. Experimental 
3.1 General 
Melting points were determined with an Electrothermal IA9200 Melting Point 
apparatus and were recorded uncorrected. 1H and 13C NMR spectra were recorded at 
200 or 300 MHz, and 50 or 75 MHz, respectively, with Bruker Avance DPX 200 or 
300 instruments. All NMR analyses were performed at 25 ºC and as solutions in 
CDCl3 with CDCl3 as reference (1H δ 7.24, 13C δ 77.0), unless stated otherwise. A 
ChemNMR prediction program was used as an aid in analysis of NMR spectra. An 
interval is given for chemical shifts when two chemically non-equivalent nuclei 
cannot be differentiated. 
IR spectra were acquired with a Perkin-Elmer 1310 Spectrometer. Mass spectra were 
recorded at 70eV with a Fisons VG Pro spectrometer. 
All reactions were carried out under an atmosphere of nitrogen or argon. After 
aqueous work-up of reaction mixtures, organic solutions were routinely dried with 
anhydrous Na2SO4 or MgSO4 and ‘evaporation under reduced pressure’ refers to 
removal of solvent on a rotary evaporator. Thin layer chromatography was carried out 
on aluminium sheets coated with 60 F254 silica gel (Merck). Compounds were 
detected by UV light and dipped in a solution of phosphomolybdic acid in ethanol, 
followed by heating. Column chromatography was performed as flash 
chromatography on silica gel (Silice 60, 40-63 µm, SDS) using gradients of EtOAc 
and hexane eluent, unless specified otherwise.  
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3.2 Assays 
3.2.1 DPPH radical scavenging 
Scavenging activity of the DPPH radical was measured as the decrease in absorbance 
at 517 nm of a MeOH solution (A517 =1.0, 2.95 mL) over a five min period after the 
addition of 50 µl DMSO solution of the test substance. Appropriate corrections were 
made for dilution and for absorbance of the reaction product (reduced DPPH). 
Calculation of radical scavenging activity was carried out as previously described.66 
3.2.2 Inhibition of 15-lipoxygenase 
Lipoxygenase activity was measured in borate buffer solutions (0.2M, pH 9.00) by 
the increase in absorbance at 234 nm from 30 to 90 s after the addition of the enzyme, 
using linoleic acid (134 µM) as substrate.67 The final enzyme concentration was 167 
U/mL. Test substances were added as DMSO solutions (final DMSO conc. 1.6%) and 
DMSO alone was added in uninhibited control experiments. Six or more parallels of 
controls and three or more parallels for each test substance solution were measured. 
The enzyme solution was kept on ice, and controls were measured at regular intervals 
to ensure constant enzyme activity throughout the experiment. 
Calculation of the enzyme activity was carried out as previously described and IC50 
values were determined by linear interpolation between the measuring points closest 
to 50% activity. Values were expressed as means ± SD while Student’s t-test was 
employed for determination of statistical significance. 
3.3 Syntheses 
Preparation of some of the following compounds has been reported previously, 
references are given. 
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General procedure to prepare 2’,4’,6’-trimethoxychalcone derivatives 
Aldehyde (2.0 mmol) and 2,4,6-trimethoxyacetophenone (29) (0.42 g, 2.0 mmol) 
were dissolved in EtOH (20-30 mL) containing NaOH (47 mg, 1.18 mmol). The 
mixture was stirred at ambient temperature until TLC showed complete conversion 
(8-42 h). Water (30 mL) was added, the reaction mixture extracted with ether (3 x 40 
mL) and the organic phase dried (Na2SO4). The solvent was removed under reduced 
pressure and the crude product purified by flash chromatography (SiO2, 
EtOAc:hexane gradient). In certain cases, the product precipitated from the reaction 
mixture and could be directly collected by filtration, recrystallized and dried under 
vacuum. 
Attempt to prepare E-1-(2,4,6-hydroxyphenyl)-3-(4-tolyl)-2-propen-1-one 
To a stirred solution of 4-methylcinnamic acid (1.63 g, 10 mmol) in dry DCM (25 
mL), oxalyl chloride (1.52 g, 12 mmol) was added dropwise. The reaction mixture 
was stirred for 2 hrs before the solvent was evaporated under reduced pressure. The 
residue was dissolved in dry THF (5 mL) and added dropwise to a solution of 
phloroglucinol (0.32 g, 2.5 mmol) and ZnCl2 (1.36 g, 10 mmol) in dry THF (20 mL). 
After 3 hrs, 10 % NaHCO3 (50 mL) was added slowly whilst on a cooling bath. The 
reaction mixture was extracted with DCM (2 x 50 mL) and washed with brine, 
followed by 10 % NaHCO3 and saturated NaHCO3. The organic phase was dried 
(Na2SO4) and the solvent evaporated. The product was purified by flash 
chromatography to yield 0.25 g (40 %) of a white crystalline product, which was 
found to be 4-chlorobutyl E-3-(4-tolyl)-2-propenoate (26). 
O
O
Cl
 
Rf 0.58 (EtOAc:hexane 1:1); IR (film, KBr) νmax/cm-1  1703 (C=O), 809 (C-Cl) ; 1H 
NMR (CDCl3, 300 MHz) δ 7.64 (d, J  16.0 Hz, 1H), 7.41 (d, J  8.0 Hz, 2H), 7.17 (d, 
J  8.0 Hz, 2H), 6.37 (d, J  16.0 Hz, 1H), 4.22 ( t, J  6.0,  2H), 3.58 (t, J  6.0 Hz, 2H), 
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2.36 (s, 3H), 1.94-1.81 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ 167.00, 144.80, 
140.35, 131.54, 129.54, 127.99, 116.76, 63.46, 44.43, 29.13, 26.11, 21.36; EIMS m/z 
(70 eV) 252 (39), 217 (17), 162 (65), 145 (100), 117 (23), 115 (27); HRMS calcd for 
C14H17O2Cl35 [M+]: 252.0917, found 252.0924. 
(±)-1-(2,4,6-Trimethoxyphenyl)-3-phenyl-2-propyn-1-ol (27) 
OH
OO
O  
Phenylacetylene (2.19 mL, 20.0 mmol) in dry THF (25 mL) was added dropwise to a 
0-5°C suspension of NaH (80 %, 0.86 g, 24.0 mmol) in dry THF (25 mL). The 
mixture was stirred for 30 min before 2,4,6-trimethoxybenzaldehyde (3.92 g, 20.0 
mmol) in dry THF (100 mL) was added dropwise. The reaction was monitored by 
TLC. The mixture was heated under reflux overnight before it was quenched with 
saturated NH4Cl (50 mL), extracted with diethyl ether (3 x 70 mL) and the organic 
phase washed with brine (50 mL). After drying (Na2SO4), the solvent was evaporated 
under reduced pressure. The products were separated by column chromatography, 
affording 1.80 g (30%) of the title compound 27 as cream-coloured crystals; mp n.d.; 
Rf 0.27 (EtOAc:hexane 40:60); IR (film, KBr) νmax/cm-1 3545 (O-H), 2258 (C≡C); 1H 
NMR (CDCl3, 300 MHz) δ 7.37 (m, 2H), 7.25-7.23 (m, 3H), 6.15 (s, 2H), 6.01 (d, J  
11.3 Hz, 1H), 3.90-3.86 (m, 7H), 3.79 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ 161.07, 
158.27, 131.65, 128.02, 127.85, 123.35, 110.55, 91.27, 90.51, 82.63, 56.64, 55.94, 
55.32; EIMS m/z (70 eV) 298 (24), 283 (38), 267 (43), 168 (100); HRMS calcd for 
C18H18O4 [M+]: 298.1205, found 298.1194. 
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E-1-(2,4,6-Trimethoxyphenyl)-3-phenyl-2-propen-1-one (28) 
OO
O O  
A solution of 27 (0.31 g, 1.0 mmol) in dry THF (15 mL) was added slowly dropwise 
to a roundbottomed flask containing LiAlH4 (0.036 g, 0.94 mmol) in dry THF (20 
mL). The mixture was heated under reflux overnight. The reaction was quenched 
with the following (in sequence): H2O (0.1 mL), NaOH (10 % aq., 0.1 mL) and H2O 
(0.3 mL). The procedure was repeated until no more precipitate formed. The mixture 
was filtrated and the precipitate washed with diethyl ether. The filtrate was dried 
(Na2SO4) and the solvent evaporated under reduced pressure to yield crude α,β-
unsaturated alcohol intermediate, which was dissolved in CHCl3 (20 mL). MnO2 
(1.04 g, 12.0 mmol) was added gradually to the mixture under magnetic stirring. 
After TLC indicated product, the mixture was filtered over Celite, Na2SO4 and SiO2, 
providing a complex mixture for which NMR indicates the presence of title 
compound 28. 
Alternative synthesis of compound 28 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and benzaldehyde affording 0.57 g (76%) as yellow 
oily solid crystals; mp 76-78 ºC (lit.47 79-81 ºC); Rf 0.25 (EtOAc:hexane 40:60); 1H 
NMR (CDCl3, 300 MHz) δ 7.49 (m, 2H), 7.37-7.31 (m, 4H), 6.94 (d, J  16.1 Hz, 1H), 
6.14 (s, 2H), 3.83 (s, 3H), 3.76 (s, 6H); 13C NMR (CDCl3, 50 MHz) δ 194.23, 162.40, 
158.83, 144.06, 135.00, 130.12, 129.00, 128.76, 128.33, 111.76, 90.68, 55.88, 55.42; 
EIMS m/z (70 eV) 298 (23), 270 (100), 195 (90); HRMS calcd for C18H18O4 [M+]: 
298.1205, found 298.1197. 
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2,4,6-Trimethoxyacetophenone (29) 
OO
O O  
Acetic anhydride (9.64 mL, 102 mmol) was added dropwise to a stirred solution of 
1,3,5-trimethoxybenzene (16.82 g, 100 mmol) and concentrated H2SO4 (4 drops) in 
1,2-dichloroethane (50 mL). The mixture was heated under reflux for 18 hrs. A 
colour change from pale green through dark blue to reddish brown occurred. The 
contents were cooled and poured into H2O (100 mL) containing EtOH (10 mL). 
Concentrated HCl (8 drops) was added and the mixture heated under reflux for 45 
min to decompose excess anhydride. The contents were cooled once again, and the 
reaction mixture extracted with diethyl ether (3 x 70 mL). The organic phase was 
washed with (in sequence) H2O (2 x 70 mL), NaHCO3 (10 % aq., 50 mL) and 
saturated NaHCO3 (50 mL). The solvent was evaporated under reduced pressure and 
the residue purified by flash chromatography to yield 6.47 g (31%) of the title 
product as a creamy white powder; Rf 0.26 (EtOAc:hexane 3:7); 1H NMR (CDCl3, 
300 MHz) δ 6.07 (s, 2H), 3.79 (s, 3H), 3.76 (s, 6H), 2.43 (s, 3H); 13C NMR (CDCl3, 
75 MHz) δ 201.61, 162.25, 158.25, 113.60, 90.49, 55.71, 55.31, 32.41. 
2,4-Dimethoxy-6-hydroxyacetophenone (30)53 
OHO
O O  
To a solution of phloroacetophenone (20.5 g, 110 mmol) and K2CO3 (22.1g, 160 
mmol) in acetone (150 mL) was added dimethyl sulphate (27.7 g, 220 mmol) slowly 
over 30 min with mechanical stirring. The solution was heated at reflux overnight and 
then poured into H2O (500 mL), which produced a creamy white precipitate. The 
material was collected on a Büchner funnel, rinsed with cold H2O (1 L) and air-dried. 
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Recrystallisation from 90% MeOH (100 mL) provided 14.7 g (68%) of the desired 
product as creamy white needles; 1H NMR (CDCl3, 300 MHz) δ 13.98 (s, 1H), 6.03 
(d, J  2.4 Hz, 1H), 5.89 (d, J  2.4 Hz, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 2.58 (s, 3H); 13C 
NMR (CDCl3, 75 MHz) δ 203.59, 167.97, 166.51, 163.32, 106.41, 93.89, 91.15, 
55.92, 51.20, 33.27. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one (31) 
O
OO
O N 2O  
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2-nitrobenzaldehyde affording 1.40 g (82%) as a 
yellow crystalline powder; mp 157-159 ºC; Rf 0.16 (EtOAc:hexane 40:60); IR (film, 
KBr) νmax/cm-1 1703 (C=O), 1520, 1363 (N=O); 1H NMR (CDCl3, 300 MHz) δ 7.98 
(dd, J  8.1 Hz, 1.1 Hz, 1H), 7.70-7.60 (m, 3H), 7.49 (m, 1H), 6.79 (d, J  16.0 Hz, 1H), 
6.13 (s, 2H), 3.83 (s, 3H), 3.77 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 194.21, 162.71, 
158.91, 148.25, 139.66, 133.47, 133.41, 131.25, 130.00, 129.20, 124.79, 110.46, 
90.59, 55.79, 55.38; EIMS m/z (70 eV) 343 (21), 195 (100); HRMS calcd for 
C18H17NO6 [M+]: 343.1055, found 343.1063. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(3-nitrophenyl)-2-propen-1-one (32) 
O
OO
O
NO2
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 3-nitrobenzaldehyde yielding 1.50 g (87%) as a 
yellow crystalline powder; mp 148-151 ºC (lit.47 146-148 ºC); Rf 0.26 (EtOAc:hexane 
40:60); IR (film, KBr) νmax/cm-1 1695 (C=O), 1514, 1375 (N=O); 1H NMR (CDCl3, 
300 MHz) δ 8.33 (m, 1H), 8.18 (m, 1H), 7.82 (d, J  7.9 Hz, 1H), 7.54 (t, J  7.9 Hz, 
 63
  
1H), 7.41 (d, J  16.1 Hz, 1H), 7.04 (d, J  16.1 Hz, 1H), 6.15 (s, 2H), 3.85 (s, 3H), 3.77 
(s, 6H); 13C NMR (CDCl3, 75 MHz) δ 192.94, 162.86, 159.10, 148.60, 140.09, 
136.93, 133.73, 131.40, 129.80, 124.21, 122.65, 111.36, 90.75, 55.92, 55.45; EIMS 
m/z (70 eV) 343 (17), 315 (100), 195 (39); HRMS calcd for C18H17NO6 [M+]: 
343.1055, found 343.1055. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(4-nitrophenyl)-2-propen-1-one (33) 
O
OO
O
NO2
 
2,4,6-Trimethoxyacetophenone (29) and 4-nitrobenzaldehyde were reacted together 
according to the general procedure. The title compound was obtained in 1.49 g (87%) 
yield as a yellow crystalline powder; mp 179-180 ºC (lit.47 176-178 ºC); Rf 0.26 
(EtOAc:hexane 40:60); IR (film, KBr) νmax/cm-1 1700 (C=O), 1524, 1367 (N=O); 1H 
NMR (CDCl3, 300 MHz) δ 8.19 (d, J  7.0 Hz, 2H), 7.64 (d, J  7.0 Hz, 2H), 7.41 (d, J  
16.0 Hz, 1H), 7.04 (d, J  16.0 Hz, 1H), 6.14 (s, 2H), 3.84 (s, 3H), 3.76 (s, 6H); 13C 
NMR (CDCl3, 75 MHz) δ 193.11, 163.38, 159.64, 148.69, 141.90, 140.16, 132.85, 
129.19, 124.45, 111.82, 91.19, 56.37, 55.90; EIMS m/z (70 eV) 343 (13), 315 (100), 
195 (41); HRMS calcd for C18H17NO6 [M+]: 343.1055, found 343.1056. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(2-bromophenyl)-2-propen-1-one (34) 
O
OO
O Br  
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This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2-bromobenzaldehyde yielding 0.60 g (80%) as a 
pale yellow crystalline powder; mp 115-117 ºC; Rf 0.26 (EtOAc:hexane 40:60); 1H 
NMR (CDCl3, 200 MHz) δ 7.70 (d, J  16.0 Hz, 1H), 7.63 (dd, J  7.8, 1.8 Hz, 1H), 
7.55 (dd, J  7.8, 1.3 Hz, 1H), 7.29 (m, 1H), 7.17 (dt, J  7.4, 1.8 Hz, 1H), 6.83 (d, J  
  
16.0 Hz, 1H),  6.14 (s, 2H), 3.83 (s, 3H), 3.76 (s, 6H); 13C NMR (CDCl3, 50 MHz) δ 
194.02, 162.54, 158.90, 142.61, 135.04, 133.25, 131.37, 130.96, 127.89, 127.62, 
125.49, 111.31, 90.66, 55.85, 55.40; EIMS m/z (70 eV) 378 (19), 376 (19), 350 (98), 
348 (100), 195 (99); HRMS calcd for C18H17Br79O4 [M+]: 376.0310, found 376.0292. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(4-bromophenyl)-2-propen-1-one (35) 
O
OO
O
Br
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 4-bromobenzaldehyde furnishing 0.72 g (63%) as a 
creamy white crystalline powder; mp 133-135 ºC; Rf 0.25 (EtOAc:hexane 40:60); 1H 
NMR (CDCl3, 300 MHz) δ 7.46 (d, J  7.0 Hz, 2H), 7.33 (d, J  7.0 Hz, 2H), 7.28 (d, J  
16.1 Hz, 1H), 6.91 (d, J  16.1 Hz, 1H), 6.13 (s, 2H), 3.83 (s, 3H), 3.75 (s, 6H); 13C 
NMR (CDCl3, 75 MHz) δ 193.70, 162.54, 158.90, 142.25, 133.97, 131.98, 129.67, 
129.46, 124.28, 111.64, 90.71, 55.89, 55.42; EIMS m/z (70 eV) 378 (15), 376 (15), 
350 (98), 348 (100), 195 (55); HRMS calcd for C18H17Br81O4 [M+]: 378.0289, found 
378.0285, C18H17Br79O4 [M+]: 376.0310, found 376.0318. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(4-tolyl)-2-propen-1-one (36) 
O
OO
O  
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 4-tolualdehyde affording 0.61 g (80%) as a creamy 
white crystalline powder; mp 122-124 ºC; Rf 0.35 (EtOAc:hexane 1:1); 1H NMR 
(CDCl3, 200 MHz) δ 7.39 (d, J  8.1 Hz, 2H), 7.31 (d, J  16.0 Hz, 1H), 7.15 (d, J  8.1 
Hz, 2H), 6.89 (d, J  16.0 Hz, 1H), 6.14 (s, 2H), 3.84 (s, 3H), 3.74 (s, 6H), 2.34 (s, 
 65
  
3H); 13C NMR (CDCl3, 50 MHz) δ 194.41, 162.32, 158.78, 144.34, 140.61, 132.25, 
129.52, 128.37, 128.14, 111.98, 90.70, 55.89, 55.43, 21.46; EIMS m/z (70 eV) 312 
(22), 284 (100), 195 (33); HRMS calcd for C19H20O4 [M+]: 312.1361, found 
312.1372. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(4-tert-butylphenyl)-2-propen-1-one (37) 
O
OO
O  
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 4-tert-butylbenzaldehyde yielding 0.49 g (55%) as 
yellow needles; mp 115-118 ºC; Rf 0.38 (EtOAc:hexane 50:50); 1H NMR (CDCl3, 
300 MHz) δ 7.33 (d, J  8.4 Hz, 2H), 7.27-7.22 (m, 3H), 6.83 (d, J  16.1 Hz, 1H), 6.06 
(s, 2H), 3.71 (s, 3H), 3.64 (s, 6H), 1.18 (s, 9H); 13C NMR (CDCl3, 75 MHz) δ 193.92, 
162.06, 158.41, 153.35, 143.69, 131.81, 127.97, 127.83, 125.40, 111.35, 90.36, 
55.42, 55.01, 34.42, 30.73; EIMS m/z (70 eV) 354 (22), 326 (100), 311 (58), 195 
(29); HRMS calcd for C22H26O4 [M+]: 354.1831, found 354.1824.  
E-1-(2,4,6-Trimethoxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one (38) 
O
OO
O
O
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and anisaldehyde yielding 0.94 g (90%) as a yellow-
white crystalline product; mp 119-120 ºC (lit.68 119-121 ºC); Rf 0.28 (EtOAc:hexane 
50:50); 1H NMR (CDCl3, 300 MHz) δ 7.45 (d, J  8.8 Hz, 2H), 7.29 (d, J  15.9 Hz, 
1H), 6.84 (d, J  8.8 Hz, 2H), 6.82 (d, J  15.9 Hz, 1H), 6.14 (s, 2H), 3.83 (s, 3H), 3.80 
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(s, 3H), 3.74 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 194.36, 162.24, 161.37, 158.72, 
144.20, 130.05, 127.68, 127.00, 114.24, 111.99, 90.72, 55.90, 55.42, 55.35; EIMS 
m/z (70 eV) 328 (33), 300 (100), 195 (35); HRMS calcd for C19H20O5 [M+]: 
328.1310, found 328.1316. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(2,3,4-trimethoxyphenyl)-2-propen-1-one (39) 
O
OO
O O
O
O
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2,3,4-trimethoxybenzaldehyde yielding 0.55 g 
(70%) as a yellow-white crystalline powder; mp 167-168 ºC; Rf 0.27 (EtOAc:hexane 
50:50); 1H NMR (CDCl3, 300 MHz) δ 7.53 (d, J  16.2 Hz, 1H), 7.26 (d, J = 8.8 Hz, 
1H), 6.86 (d, J  16.2 Hz, 1H), 6.65 (d, J = 8.8 Hz, 1H), 6.11 (s, 2H), 3.84 (s, 3H), 
3.80 (s, 6H), 3.78 (s, 3H), 3.71 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 194.67, 162.14, 
158.59, 155.37, 153.22, 142.25, 139.46, 128.12, 123.13, 121.96, 111.87, 107.63, 
90.63, 61.34, 60.79, 55.95, 55.76, 55.32; EIMS m/z (70 eV) 357 (100), 195 (11); 
HRMS calcd for C21H24O7 [M+]: 388.1522, found 388.1510. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(2,4,5-trimethoxyphenyl)-2-propen-1-one (40) 
O
OO
O O
O
O
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2,4,5-trimethoxybenzaldehyde yielding 0.33 g 
(50%) as a yellow powder; mp 107-109 ºC; Rf 0.17 (EtOAc:hexane 50:50); 1H NMR 
(CDCl3, 300 MHz) δ 7.63 (d, J  16.1 Hz, 1H), 7.02 (s, 1H), 6.87 (d, J  16.1 Hz, 1H), 
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6.45 (s, 1H), 6.14 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.79 (s, 3H), 3.74 
(s, 6H); 13C NMR (CDCl3, 75 MHz) δ 195.29, 162.51, 159.10, 154.52, 152.64, 
143.71, 140.14, 127.60, 116.01, 111.34, 97.43, 91.24, 91.00, 56.89, 56.44, 56.34, 
56.22, 55.84; EIMS m/z (70 eV) 388 (14), 357 (100), 195 (12); HRMS calcd for 
C21H24O7 [M+]: 388.1522, found 388.1523. 
E-1,3-bis-(2,4,6-Trimethoxyphenyl)-2-propen-1-one (41) 
O
OO
O O
OO
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2,4,6-trimethoxybenzaldehyde yielding 0.36 g 
(46%) as a pale yellow crystalline powder; mp 158-160 ºC (lit.69 157 °C); Rf  0.10 
(EtOAc:hexane 50:50); 1H NMR (CDCl3, 300 MHz) δ 7.76 (d, J  16.3 Hz, 1H), 7.28 
(d, J  16.3 Hz, 1H), 6.13 (s, 2H), 6.05 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.78 (s, 6H), 
3.72 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 196.37, 162.87, 161.77, 161.35, 158.60, 
136.42, 129.15, 112.72, 106.40, 90.80, 90.47, 55.88, 55.67, 55.37, 55.30; EIMS m/z 
(70 eV) 388 (10), 357 (100), 195 (13); HRMS calcd for C21H24O7 [M+]: 388.1522, 
found 388.1505. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one (42) 
O
OO
O
O
O
O
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 3,4,5-trimethoxybenzaldehyde to yield 1.36 g 
(70%) as a pale yellow crystalline powder; mp 137-140 ºC; Rf 0.40 (EtOAc:hexane 
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3:1); 1H NMR (CDCl3, 300 MHz) δ 7.22 (d, J  16.0 Hz, 1H), 6.84 (d, J  16.0 Hz, 1H), 
6.72 (s, 2H), 6.15 (s, 2H), 3.84 (s, 12H), 3.75 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 
194.70, 162.80, 159.11, 153.74, 144.78, 140.43, 130.85, 128.90, 111.98, 105.89, 
91.09, 61.29, 56.51, 55.90, 55.83; EIMS m/z (70 eV) 388 (100), 360 (79), 345 (95), 
195 (38); HRMS calcd for C21H24O7 [M+]: 388.1522, found 388.1509. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (43) 
O
OO
O
OH
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4-Hydroxybenzaldehyde (2.44 g, 20 mmol) and para-toluenesulphonic acid (0.091 g, 
0.48 mmol) were stirred in dry DCM (80 ml), and then 3,4-dihydro-2H-pyran (5.05 g, 
60 mmol) in dry DCM (20 ml) was added dropwise. The reaction mixture was stirred 
at room temperature until all the components dissolved, then left for 1 hour after 
which H2O (50 ml) and then aqueous NaHCO3 (30 ml) was added. The mixture was 
washed with 10 % NaHCO3 (2 x 50 ml), once with H2O (40 ml), then dried (Na2SO4) 
and evaporated under reduced pressure. The crude product was purified by flash 
chromatography yielding the crude 4-(tetrahydropyran-2-yloxy)-benzaldehyde. The 
title compound was prepared from 2,4,6-trimethoxyacetophenone (29) and 4-
(tetrahydropyran-2-yloxy)-benzaldehyde according to the general procedure. 3M HCl 
(5 mL) in MeOH (5 mL) was added dropwise to a solution of the crude residue in 
MeOH (20 mL). After 2 hrs, 10 % NaHCO3 solution (5 mL) was added and the 
mixture extracted with DCM (3 x 40 mL). The organic phase was dried (Na2SO4) and 
the solvent evaporated under reduced pressure. The residue was purified by column 
chromatography furnishing 0.30 g (total yield 30%) as a bright yellow powder; mp 
198-200 ºC; Rf 0.17 (EtOAc:hexane 1:1); 1H NMR (acetone-d6, 300 MHz) δ 7.49 
(dm, J  8.7 Hz, 2H), 7.20 (d, J  16.1 Hz, 1H), 6.87 (dm, J  8.7 Hz, 2H), 6.75 (d, J  
16.1 Hz, 1H), 6.29 (s, 2H), 3.85 (s, 3H), 3.73 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 
196.55, 162.62, 159.54, 158.83, 146.40, 130.46, 126.37, 125.63, 116.11, 111.10, 
  
90.68, 55.81, 55.39; EIMS m/z (70 eV) 314 (25), 286 (100), 195 (33); HRMS calcd 
for C18H18O5 [M+]: 314.1154, found 314.1157. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one (44) 
O
OO
O
OH
OH
 
3,4-Bis-(tetrahydropyran-2-yloxy)-benzaldehyde was obtained using six equivalents 
of 3,4-dihydro-2H-pyran according to the procedure for 4-(tetrahydropyran-2-yloxy)-
benzaldehyde. The title compound was synthesised from 2,4,6-
trimethoxyacetophenone (29) and crude 3,4-bis-(tetrahydropyran-2-yloxy)-
benzaldehyde following the general procedure. Flash chromatography furnished 0.19 
g (total yield 14%) of the title compound as a bright yellow crystalline powder; mp 
173-177 ºC; Rf 0.73 (DCM:MeOH 60:40); 1H NMR (CDCl3, 300 MHz) δ 7.53 (bs, 
1H), 7.36 (bs, 1H), 7.25 (d, J  15.9 Hz, 1H), 7.04 (d, J  1.5 Hz, 1H), 6.80-6.73 (m, 
3H), 6.08 (s, 2H), 3.78 (s, 3H), 3.66 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 196.31, 
162.62, 158.77, 147.57, 146.90, 144.44, 127.14, 125.96, 122.92, 115.14, 114.46, 
110.96, 90.64, 55.71, 55.34; EIMS m/z (70 eV) 330 (24), 302 (100), 195 (40); HRMS 
calcd for C18H18O6 [M+]: 330.1103, found 330.1095. 
 
E-1-(2,4,6-Trimethoxyphenyl)- 3-(pyridin-2-yl)-2-propen-1-one (45) 
O
OO
O
N
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and pyridin-2-aldehyde affording 0.15 g (25%) as a 
bright yellow crystalline powder; mp 100-102 ºC (lit.47 100-102 ºC); Rf 0.10 
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(EtOAc:hexane 40:60), 0.32 (EtOAc:hexane 1:1); 1H NMR (CDCl3, 200 MHz) δ 
8.60 (dd, J  4.8, 0.7 Hz, 1H), 7.68 (ddd, J  7.7, 7.7, 0.9 Hz, 1H), 7.47 (m, 1H), 7.39 
(d, J  15.9 Hz, 1H), 7.29 (d, J  15.9 Hz, 1H), 7.20 (m, 1H), 6.11 (s, 2H), 3.82 (s, 3H), 
3.74 (s, 6H); 13C NMR (CDCl3, 50 MHz) δ 194.30, 162.55, 158.91, 153.83, 149.93, 
142.50, 136.63, 132.33, 123.91, 123.86, 111.56, 90.65, 55.84, 55.42; EIMS m/z (70 
eV) 299 (35), 240 (100), 195 (32); HRMS calcd for C17H17 NO4 [M+]: 299.1157, 
found 299.1160. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(pyridin-3-yl)-2-propen-1-one (46) 
O
OO
O
N
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and pyridin-3-aldehyde affording 0.29 g (48%) as 
yellow crystalline powder; mp 119-123 ºC (lit.47 123-125 ºC); Rf 0.18 (EtOAc:hexane 
3:1); 1H NMR (CDCl3, 300 MHz) δ 8.62 (d, J  1.3 Hz, 1H), 8.47 (dd, J  4.6, 1.0 Hz, 
1H), 7.77 (dt, J  8.0, 1.8 Hz, 1H), 7.28 (d, J  16.1 Hz, 1H), 7.22 (dd, J  8.0, 4.6 Hz, 
1H), 6.94 (d, J  16.1 Hz, 1H), 6.09 (s, 2H), 3.76 (s, 3H), 3.68 (s, 6H); 13C NMR 
(CDCl3, 75 MHz) δ 192.92, 162.47, 158.70, 150.43, 149.59, 139.24, 134.08, 130.52, 
130.42, 123.42, 111.02, 90.46, 55.59, 55.15; EIMS m/z (70 eV) 299 (25), 271 (100), 
195 (48); HRMS calcd for C17H17 NO4 [M+]: 299.1157, found 299.1149. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(pyridin-4-yl)-2-propen-1-one (47) 
O
OO
O
N
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and pyridin-4-aldehyde affording 0.24 g (40%) as a 
yellow oil; Rf 0.18 (EtOAc:hexane 3:1); 1H NMR (CDCl3, 200 MHz) δ 8.78 (d, J  6.7 
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Hz, 2H), 7.56 (d, J  6.7 Hz, 2H), 7.50 (d, J  16.0 Hz, 1H), 7.28 (d, J  16.0 Hz, 1H), 
6.15 (s, 2H), 4.02 (s, 3H), 3.95 (s, 6H); 13C NMR (CDCl3, 50 MHz) δ 193.24, 163.32, 
159.50, 150.61, 142.84, 140.07, 133.07, 122.42, 111.53, 91.09, 55.24, 55.81; EIMS 
m/z (70 eV) 299 (30), 271 (100), 195 (83); HRMS calcd for C17H17NO4 [M+]: 
299.1157, found 299.1154. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(quinolin-2-yl)-2-propen-1-one (48) 
O
OO
O
N
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2-quinolinecarboxaldehyde yielding 0.51 g (75%) 
as a beige powder; mp 105-108 ºC; Rf 0.21 (EtOAc:hexane 40:60), 0.33 
(EtOAc:hexane 50:50); 1H NMR (CDCl3, 300 MHz) δ  8.14 (d, J  8.5 Hz, 1H), 8.04 
(d, J  8.5 Hz, 1H), 7.79 (d, J  7.8 Hz, 1H), 7.72-7.67 (m, 2H), 7.56-7.50 (m, 2H), 7.33 
(d, J  16.2 Hz, 1H), 6.14 (s, 2H), 3.84 (s, 3H), 3.76 (s, 6H); 13C NMR (CDCl3, 75 
MHz) δ 194.82, 162.58, 158.89, 154.28, 148.22, 143.85, 136.52, 133.81, 129.93, 
129.59, 127.89, 127.51, 127.22, 119.86, 111.17, 90.74, 55.82, 55.43; EIMS m/z (70 
eV) 349 (56), 290 (100), 195 (30); HRMS calcd for C21H19NO4 [M+]: 349.1314, 
found 349.1323. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(quinolin-3-yl)-2-propen-1-one (49) 
O
OO
O
N
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 3-quinolinecarboxaldehyde yielding 0.74 g (85%) 
as a pale yellow crystalline powder; mp 158-160 ºC; Rf 0.09 (EtOAc:hexane 2:3), 
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0.19 (EtOAc:hexane 1:1); 1H NMR (CDCl3, 200 MHz) δ 9.06 (d, J  2.0 Hz, 1H), 8.21 
(d, J  2.0 Hz, 1H), 8.07 (d, J  8.4 Hz, 1H), 7.81 (dd, J  8.4, 1.0 Hz, 1H), 7.71 (dt, J  
8.4, 1.5 Hz, 1H), 7.57-7.49 (m, 2H), 7.16 (d, J  15.9 Hz, 1H), 6.15 (s, 2H), 3.84 (s, 
3H), 3.76 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 193.62, 163.18, 159.51, 149.96, 
148.86, 140.23, 136.01, 130.92, 130.87, 129.75, 128.72, 128.51, 128.11, 127.73, 
111.95, 90.98, 56.36, 55.89; EIMS m/z (70 eV) 349 (19), 321 (100), 195 (27); HRMS 
calcd for C21H19NO4 [M+]: 349.1314, found 349.1308. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(quinolin-4-yl)-2-propen-1-one (50) 
O
OO
O
N
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 4-quinolinecarboxaldehyde yielding 0.58 g (85%) 
as pale yellow crystals; mp 139-143 ºC (lit.47 139-141 ºC); Rf 0.12 (EtOAc:hexane 
3:1), 0.13 (EtOAc:hexane 50:50); 1H NMR (CDCl3, 200 MHz) δ 8.90 (d, J  4.5 Hz, 
1H), 8.14 (d, J  16.0 Hz, 1H), 8.09 (t, J  8.8 Hz, 2H), 7.73 (dt, J  6.9, 1.3 Hz, 1H), 
7.63-7.53 (m, 2H), 7.13 (d, J  16.0 Hz, 1H), 6.20 (s, 2H), 3.80 (s, 3H), 3.79 (s, 6H); 
13C NMR (CDCl3, 75 MHz) δ 192.32, 162.98, 159.33, 150.00, 148.54, 140.76, 
136.67, 134.45, 130.05, 129.52, 126.98, 126.18, 123.33, 118.10, 111.42, 90.71, 
55.87, 55.40; EIMS m/z (70 eV) 349 (21), 321 (100), 290 (18), 195 (49); HRMS 
calcd for C21H19NO4 [M+]: 349.1314, found 349.1321. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(5-indolyl)-2-propen-1-one (52) 
O
OO
O
NH
 
 73
  
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and indole-5-carboxaldehyde yielding 0.13 g (19%) as 
yellow crystals; Rf 0.20 (EtOAc:hexane 50:50); 1H NMR (CDCl3, 300 MHz) δ 8.58 
(bs, 1H),  7.74 (s, 1H), 7.48 (d, J  16.0 Hz, 1H), 7.67 (dd, J  8.6, 1.5 Hz, 1H), 7.33 (d, 
J   8.6 Hz, 1H), 7.18 (t, J  4.5 Hz, 1H), 6.94 (d, J  16.0 Hz, 1H), 6.51 (m, 1H), 6.15 (s, 
2H),  3.84 (s, 3H), 3.72 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 194.98, 162.17, 
158.68, 147.17, 137.15, 128.13, 126.85, 126.45, 125.34, 122.86, 121.83, 111.61, 
103.28, 90.75, 55.89, 55.43. MS analysis was not performed and the melting point 
was not determined due to the instability of the compound. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(thiophen-2-yl)-2-propen-1-one (53) 
O
OO
O
S
 
This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and thiophene-2-carboxaldehyde furnishing 0.56 g 
(72%) as a yellow crystalline powder; mp 89-93 ºC; Rf 0.23 (EtOAc:hexane 40:60); 
1H NMR (CDCl3, 200 MHz) δ 7.45 (d, J  15.7 Hz, 1H), 7.35 (d, J  5.1 Hz, 1H), 7.20 
(d, J  3.7 Hz, 1H), 7.01 (dd, J  5.1, 3.7 Hz, 1H), 6.74 (d, J  15.7 Hz, 1H),  6.13 (s, 
2H), 3.83 (s, 3H), 3.77 (s, 6H); 13C NMR (CDCl3, 50 MHz) δ 193.25, 162.17, 158.46, 
139.90, 136.15, 130.87, 128.42, 127.89, 127.71, 111.11, 90.38, 55.52, 55.10; EIMS 
m/z (70 eV) 304 (14), 276 (100), 195 (23); HRMS calcd for C16H16SO4 [M+]: 
304.0769, found 304.0761. 
E-1-(2,4,6-Trimethoxyphenyl)-3-(furan-2-yl)-2-propen-1-one (54) 
O
OO
O
O
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This compound was prepared according to the general procedure from 2,4,6-
trimethoxyacetophenone (29) and 2-furaldehyde yielding 0.26 g (36%) as a bright 
yellow powder; mp 91-93 ºC; Rf 0.21 (EtOAc:hexane 40:60); 1H NMR (CDCl3, 300 
MHz) δ 7.45 (d, J  1.3 Hz, 1H), 7.10 (d, J  15.8 Hz, 1H), 6.81 (d, J  15.8 Hz, 1H), 
6.57 (d, J  3.3 Hz, 1H), 6.43 (dd, J  3.3, 1.7 Hz, 1H),  6.12 (s, 2H), 3.82 (s, 3H), 3.74 
(s, 6H); 13C NMR (CDCl3, 75 MHz) δ 193.66, 162.38, 158.82, 151.45, 144.73, 
130.24, 126.69, 115.12, 112.40, 111.71, 90.69, 55.87, 55.41; EIMS m/z (70 eV) 288 
(16), 260 (100), 195 (21); HRMS calcd for C16H16O5 [M+]: 288.0997, found 
288.0997. 
E-1-(2,4-Dimethoxy-6-hydroxyphenyl)-3-(quinolin-4-yl)-2-propen-1-one (55) 
O
OO
OH
N
 
4-Quinolinecarboxaldehyde (1.57 g, 10 mmol) in EtOH (30 mL) was added slowly 
dropwise to a solution of 2,4-dimethoxy-6-hydroxyacetophenone (30) (1.96 g, 10 
mmol) and NaOH (0.24 g, 5.9 mmol) in EtOH (50 mL). The mixture turned green. 
The reaction was monitored by TLC. After 5 h, water (50 mL) was added. The 
mixture was extracted with diethyl ether (3 x 50 mL), dried (MgSO4) and the organic 
phase evaporated. The residue was purified by flash chromatography, affording 0.32 
g (10%) as an orange product; mp 162-164 °C; Rf 0.12 (EtOAc:hexane 3:1); 1H NMR 
(methanol-d4, 300 MHz, 50ºC) δ 8.91 (d, J  4.6 Hz, 1H), 8.17 (d, J  8.6 Hz, 1H), 8.05 
(d, J  8.6 Hz, 1H), 7.74 (m, 1H), 7.69 (d, J  4.6 Hz, 1H), 7.61 (m, 1H), 6.11 (m, 1H), 
6.05 (d, J  2.3 Hz, 1H), 6.00 (d, J  2.3 Hz, 1H), 3.81 (s, 3H), 3.71 (s, 3H), 3.63 (m, 
1H), 3.48 (m, 1H); 13C NMR not available due to poor solubility; EIMS m/z (70 eV) 
353 (11), 335 (10), 207 (17), 196 (20), 181 (100); HRMS calcd for C20H17NO4 [M+]: 
335.1157, found 335.1153.  
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(±)-5,7-Dimethoxy-2-phenyl-chroman-4-one (56) 
O
O
O
O
 
NaOH (0.24 g, 5.9 mmol) in EtOH (50 mL) was added slowly to a roundbottomed 
flask containing 2,4-dimethoxy-6-hydroxyacetophenone (30) (1.96 g, 10 mmol) and 
benzaldehyde (1.06 g, 10 mmol). The mixture was heated at reflux overnight with 
mechanical stirring. H2O (70 mL) was added, the mixture extracted with diethyl ether 
(3 x 70 mL) and the organic phase dried (MgSO4) and evaporated under reduced 
pressure. The residue was purified by flash chromatography yielding 0.42 g (15%) as 
greyish-white crystals; mp 139-141 °C; Rf 0.21 (EtOAc:hexane 1:1); 1H NMR 
(CDCl3, 300 MHz) δ 7.36-7.20 (m, 5H), 6.03 (d, J  2.3 Hz, 1H), 5.97 (d, J  2.3 Hz, 
1H), 5.27 (dd, J  13.0, 3.0 Hz, 1H), 3.76 (s, 3H), 3.68 (s, 3H), 2.88 (dd, J  16.5, 13.0 
Hz, 1H), 2.66 (dd, J  16.5, 3.0 Hz, 1H); 13C NMR (CDCl3, 75 MHz) δ 188.53, 
165.49, 164.50, 161.83, 138.45, 128.34, 128.19, 125.71, 105.53, 93.18, 92.69, 78.69, 
55.66, 55.15, 45.15; EIMS m/z (70 eV) 284 (66), 207 (19), 180 (100), 152 (29), 137 
(23); HRMS calcd for C17H16O4 [M+]: 284.1048, found 284.1061. 
(±)-2-(4-tert-Butylphenyl)-5,7-dimethoxy-chroman-4-one (57) 
O
O
O
O
 
NaOH (0.24 g, 5.9 mmol) in EtOH (40 mL) was added slowly to a roundbottomed 
flask containing 2,4-dimethoxy-6-hydroxyacetophenone (30) (1.96 g, 10 mmol) and 
4-tert-butylbenzaldehyde (1.62 g, 10 mmol) with mechanical stirring. The mixture 
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was heated at reflux for 2-3 hrs, cooled and left at room temperature overnight. H2O 
(50 mL) was added, the mixture extracted with diethyl ether (3 x 70 mL) and the 
organic phase dried (MgSO4) and evaporated under reduced pressure. The residue 
was purified by flash chromatography affording 0.69 g (20%) as pale yellow crystals; 
mp 147-150 °C; Rf 0.29 (EtOAc:hexane 1:1); 1H NMR (CDCl3, 300 MHz) δ 7.36 (m, 
4H), 6.08 (d, J  2.3 Hz, 1H), 6.02 (d, J  2.3 Hz, 1H), 5.32 (dd, J  13.0, 3.0 Hz, 1H), 
3.82 (s, 3H), 3.74 (s, 3H), 2.98 (dd, J  16.5, 13.0 Hz, 1H), 2.72 (dd, J  16.5, 3.0 Hz, 
1H), 1.28 (s, 9H); 13C NMR (CDCl3, 75 MHz) δ 189.26, 165.84, 164.98, 162.20, 
151.70, 135.59, 125.92, 125.62, 105.94, 93.48, 93.01, 79.04, 56.06, 55.48, 45.29, 
34.56, 31.22; EIMS m/z (70 eV) 340 (66), 207 (26), 180 (100), 152 (17), 145 (13), 
137 (13); HRMS calcd for C21H24O4 [M+]: 340.1674, found 340.1669.  
(±)-5,7-Dimethoxy-2-(4-methoxyphenyl)-chroman-4-one (58) 
OO
O O
O
 
The compound was prepared from 2,4-dimethoxy-6-hydroxyacetophenone (30) and 
4-methoxybenzaldehyde in the same way as described for compound 57, furnishing 
0.03 g (1%) as pale yellow crystals; mp 105-106 °C (lit.70 117-118 °C); Rf 0.33 
(EtOAc:hexane 1:1); 1H NMR (CDCl3, 300 MHz) δ 13.74 (s, 1H), 7.32 (d, J  8.7Hz, 
2H), 6.93 (d, J  8.7Hz, 2H), 6.05 (d, J  2.3 Hz, 1H), 5.88 (d, J  2.3 Hz, 1H), 5.21 (m, 
1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.77 (s, 3H), 3.44-3.28 (m, 3H); 13C NMR (CDCl3, 75 
MHz) δ 204.21, 167.76, 166.44, 162.86, 158.93, 135.57, 127.11, 113.79, 105.88, 
93.69, 90.96, 69.75, 55.59, 55.55, 55.23, 52.63; EIMS m/z (70 eV) 314 (13), 196 
(26), 181 (100), 135 (41); HRMS calcd for C18H18O5 [M+]: 314.1154, found 
314.1155. 
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(±)-5,7-Dimethoxy-2-(quinolin-4-yl)-chroman-4-one (59) 
OO
O O
N
 
To a solution of 1-(2,4,6-trimethoxyphenyl)-3-(quinolin-4-yl)-2-propen-1-one (50) 
(1.75g, 5 mmol) in anhydrous DCM (30 mL) was added a 1M solution of BBr3 (5.5 
mL, 5.5 mmol) in DCM  dropwise over 15 min at room temperature with magnetic 
stirring. A reddish-brown precipitate was formed during the addition. After stirring 
for 6 hrs, the reaction was quenched by addition of EtOH (30 mL) and the solvent 
was evaporated under reduced pressure. The red residue was triturated with boiling 
50% EtOH (60 mL). After cooling to room temperature, the red solid was collected 
on a Büchner funnel, washed with 50% EtOH (100 mL) and air-dried. 
Recrystallisation from 80% EtOH (300 mL) provided 0.95 g (57 %) of the title 
product as a red powder; mp n.d. (decomposed upon heating); Rf 0.14 
(EtOAc:hexane 3:1); 1H NMR (methanol-d4, 300 MHz) δ 9.02 (d, J  5.5 Hz, 1H), 
8.52 (d, J  8.5 Hz, 1H), 8.17-7.94 (m, 4H), 6.08 (m, 2H), 5.11 (dd, J  8.2, 4.2 Hz, 
1H), 4.03 (dd, J  14.9, 4.2 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.76-3.71 (m, 1H); 13C 
NMR n.d. due to very poor solubility; EIMS m/z (70 eV) 335 (100), 207 (57), 143 
(47); HRMS calcd for C20H17NO4 [M+]: 335.1157, found 335.1165. 
E-1-(2,4-Dimethoxy-6-hydroxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one 
(60) 
O
OHO
O
O
 
1/3 of the AlCl3 (total 1.33 g, 10 mmol) was added to a solution of E-1-(2,4,6-
trimethoxyphenyl)-3-(4-methoxyphenyl)-propenone (38) (1.64 g, 5 mmol) in dry 
DCM (30 mL). The mixture was heated on reflux for 1 h, after which another 1/3 of 
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the AlCl3 was slowly added. The reaction was left with magnetic stirring for 30 min 
before the remaining AlCl3 was added. When a new product was detected on TLC 
(hvor lenge), the reaction mixture was dissolved in DCM until complete dissolution 
had occurred. The mixture was extracted with H2O. HCl was added for better 
separation of the phases. The organic phase was dried (MgSO4) and the solvent 
evaporated under reduced pressure. The residue was purified by column 
chromatography, yielding 0.45 g (28%) as yellow crystals; mp 117-118 °C (lit.68 113-
114 ºC); Rf 0.28 (EtOAc:hexane 1:1); IR (film, KBr) νmax/cm-1 3584 (OH, H-bonded); 
1H NMR (CDCl3, 300 MHz) δ 14.33 (s, 1H), 7.89 (d, J 15.5 Hz, 1H), 7.75 (d, J 15.5 
Hz, 1H), 7.67 (d, J  8.4 Hz, 1H), 6.98 (d, J  8.4 Hz, 1H), 6.08 (s, 2H), 3.98 (s, 3H), 
3.85 (s, 6H); 13C NMR (CDCl3, 75 MHz) δ 192.56, 168.34, 165.99, 162.43, 161.33, 
142.42, 130.07, 128.29, 125.10, 114.33, 106.33, 93.79, 91.19, 55.80, 55.53, 55.36; 
EIMS m/z (70 eV) 314 (100), 207 (33), 180 (34); HRMS calcd for C18H18O5 [M+]: 
314.1154, found 314.1147. 
(±)-4-Isobutyl-5,7-dimethoxy-2-phenyl-chroman-4-ol (61) 
HO
OO
O
 
(±)-5,7-Dimethoxy-2-phenyl-chroman-4-one (56) (0.35 g, 1.2 mmol) in dry THF (20 
ML) was cooled between –10 and -5°C in a freezing mixture of crushed ice and 
CaCl2. Isobutylmagnesium bromide (2.0M in diethyl ether, 0.75 mL, 1.5 mmol) was 
added slowly to the mixture under magnetic stirring. After 1 h, a saturated NH4Cl 
solution (10 mL) was added slowly, while still on ice, and then H2O (20 mL) was 
added before extraction with diethyl ether (2 x 20 mL). The organic phase was dried 
(MgSO4) and the solvent evaporated under reduced pressure. The residue was 
purified by flash chromatography, yielding 0.25 g (61 %) as a yellow solid; mp n.d.; 
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Rf 0.65 (EtOAc:hexane 3:1); 1H NMR (CDCl3, 300 MHz) δ 7.46-7.33 (m, 5H), 6.10 
(s, 2H), 5.07 (dd, J  12.5, 1.9 Hz, 1H), 4.14 (s, 1H), 3.87 (s, 3H), 3.73 (s, 3H), 2.42 
(dd, J  13.8, 1.9 Hz, 1H), 2.21 (m, 1H), 2.12-1.89 (m, 3H), 1.06 (d, J  6.3 Hz, 3H), 
0.97 (d, J  6.3 Hz, 3H); 13C NMR (CDCl3, 75 MHz) δ 160.03, 158.52, 155.12, 
140.73, 128.63, 128.22, 126.24, 111.04, 94.03, 92.69, 76.30, 71.48, 55.58, 55.29, 
48.99, 40.68, 25.32, 24.72, 23.64.  
(±)-2-(4-tert-Butylphenyl)-4-isobutyl-5,7-dimethoxy-chroman-4-ol (62) 
OO
O HO
 
The compound was obtained from 2-(4-tert-butyl-phenyl)-5,7-dimethoxy-chroman-4-
one (58) and isobutylmagnesium bromide in the same procedure as described for 61, 
yielding 0.27 g (52 %) of the title compound; mp n.d.; Rf 0.68 (EtOAc:hexane 3:1); 
1H NMR (CDCl3, 200 MHz) δ diastereomer 1: 7.47-7.37 (m, 4H), 6.11 (s, 2H), 5.06 
(dd, J  12.3, 2.1 Hz, 1H), 4.16 (s, 1H), 3.87 (s, 3H), 3.73 (s, 3H), 2.44 (dd, J  2.1, 13.8 
Hz, 1H), 2.23 (dd, J  12.8, 13.8 Hz, 1H), 2.06-1.96 (m, 3H), 1.34 (s, 9H), 1.08 (d, J  
6.2 Hz, 3H), 0.98 (d, J  6.2 Hz, 3H), diastereomer 2: 3.90 (s, 0.6H), 3.82 (s, 0.6H); 
13C NMR not analysed due to multiple signals; EIMS m/z (70 eV) 380 (7), 341 (100), 
323 (23), 181 (28). 
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(±)-4-Isobutyl-5,7-dimethoxy-2-phenyl-chroman (63) 
OO
O
 
(±)-4-Isobutyl-5,7-dimethoxy-2-phenyl-chroman-4-ol (61) (0.28 g, 0.8 mmol) was 
dissolved in EtOH (10 mL) and 5 drops of conc. H2SO4 were added. The mixture was 
hydrogenated at atmospheric pressure for 32 hrs using Pd/C (0.15 g, 10%) as catalyst. 
The crude product was purified by dry-column flash chromatography; 1H NMR 
(CDCl3, 200 MHz) δ 7.45-7.26 (m, 5H), 6.15 (d, J  2.4 Hz, 1H), 6.10 (d, J  2.4 Hz, 
1H), 4.83 (dd, J  2.4, 10.7 Hz, 1H), 3.78 (s, 3H), 3.74 (s, 3H), 3.11 (m, 1H), 2.41 
(ddd, J  2.4, 8.2, 14.2 Hz, 1H), 1.94-1.81 (m, 2H), 1.64 (m, 1H), 1.06 (m, 1H), 0.93 
(d, J  6.4 Hz, 3H), 0.81 (d, J  6.4 Hz, 3H); 13C (CDCl3, 50 MHz) δ 159.23, 159.00, 
157.50, 141.84, 128.46, 127.69, 125.69, 109.34, 93.93, 92.54, 77.99, 55.25, 55.19, 
45.03, 38.23, 28.98, 25.53, 24.21, 21.01. 
(±)-2-(4-tert-Butylphenyl)-4-isobutyl-5,7-dimethoxy-chroman (64) 
OO
O
 
A solution of (±)-2-(4-tert-Butyl-phenyl)-4-isobutyl-5,7-dimethoxy-chroman-4-ol 
(62) (0.27 g, 0.7 mmol) and 5 drops of conc. H2SO4 in EtOH (15 mL) was 
hydrogenated on a Parr apparatus for 20 hrs using Pd/C (0.20g, 10%) as catalyst. The 
mixture was purified by dry-column flash chromatography; 1H NMR and 13C NMR 
not analyzed due to multiple signals caused by stereogenic centre. 
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4-[3-(2,4,6-Trimethoxyphenyl)-buta-1,3-dienyl]-quinoline (66) 
CH2
OO
O
N
 
To a stirred solution of trimethylsilylmethylmagnesium chloride (0.52 g, 3.6 mmol) 
in dry THF (5 mL) was added a solution of E-1-(2,4,6-trimethoxyphenyl)-3-
(quinolin-4-yl)-2-propen-1-one (50) (1.05 g, 3 mmol) in dry THF (5 mL), slowly 
dropwise. The resulting mixture was refluxed with continued stirring for 1 h, allowed 
to cool and left at room temperature for another 3 hrs. H2O (20 mL) was added along 
with NaHCO3 (10 %, 10 mL), the mixture extracted with diethyl ether (3 x 30 mL) 
the organic phase dried (MgSO4) and the solvent evaporated under reduced pressure. 
The structure of the intermediate alcohol 65 was analysed by NMR and IR. 
Potassium hydride (1.20 g 30% dispersion in oil, 0.36 mmol) was washed with 
hexane (10 mL), which was removed by a pipette. To the residue was added dry THF 
(10 mL), and then a solution of the intermediate 65 in dry THF (10 mL) was added. 
The mixture was heated under reflux overnight. The mixture was poured into cold 
NH4Cl (10 %, 50 mL) overlaid with diethyl ether (40 mL). The aqueous phase was 
extracted with diethyl ether (50 mL), the organic phases combined, washed with 
brine (40 mL), dried (MgSO4) and the solvent evaporated under reduced pressure. 
The products could not be separated by flash chromatography, thus the yield was not 
established. 
(±)-1-(2,4,6-Trimethoxyphenyl)- 3-phenyl-butan-1-one (67) 
O
OO
O  
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MeLi (1.6M in diethyl ether, 2.25 mL) was added carefully to a solution of E-1-
(2,4,6-trimethoxyphenyl)-3-phenyl-2-propen-1-one (28) (0.884 g, 3.0 mmol) in dry 
THF (20 mL). After 2 hrs, the reaction was quenched with saturated NH4Cl (10 mL), 
and the mixture was extracted with diethyl ether (2 x 40 mL). The organic phase was 
washed with brine, dried (MgSO4) and the solvent evaporated under reduced 
pressure. Half of the crude intermediate was dissolved in MeOH (10 mL), 
concentrated H2SO4 (1 drop) was added and TLC after 3 min showed formation of a 
product. A 10 % solution of NaHCO3 (10 mL) was added and the mixture was 
extracted with DCM (2 x 20 mL). The organic phase was dried (MgSO4) and the 
solvent evaporated giving 0.12 g (overall 25%) of the title compound 67 as reddish-
brown crystals; mp n.d.; Rf 0.36 (EtOAc:hexane 30:70); 1H NMR (CDCl3, 300 MHz) 
δ 7.26-7.13 (m, 5H), 6.07 (s, 2H), 3.80 (s, 3H), 3.70 (s, 6H), 3.54-3.34 (m, 1H), 3.09 
(dd, J  16.6, 5.6 Hz, 1H), 2.97 (dd, J  16.6, 8.7 Hz), 1.30 (d, J  6.9 Hz, 3H); 13C NMR 
(CDCl3, 75 MHz) δ 203.04, 162.14, 158.06, 146.89, 128.13, 126.83, 125.78, 113.48, 
90.44, 55.59, 55.27, 52.95, 35.35, 21.88; EIMS m/z (70 eV) 314 (8), 297 (86), 195 
(100), 168 (32); HRMS calcd for C19H22O4 [M+]: 314.1518, found 314.1520.  
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